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Abstract 
Prescribing for older patients is challenging. The prevalence of diseases increases 
with advancing age and causes extensive drug use. Impairments in cognitive, 
sensory, social and physical functioning, multimorbidity and comorbidities, as well as 
age-related changes in pharmacokinetics and pharmacodynamics that impair the 
functional reserve of multiple systems and organs all add to the complexity of 
prescribing. Consequently, older people are at particular risk for adverse drug events.  
This study is a cross-sectional assessment of all long-term residents aged ≥ 65 
years in all nursing homes in Helsinki, Finland. The residents’ health status was 
assessed and data on their demographic factors, health and medications were 
collected from their medical records in February 2003.  
This study assesses some essential issues in prescribing for older people: 
psychotropic drugs (Paper I), laxatives (Paper II), vitamin D and calcium supplements 
(Paper III), potentially inappropriate drugs for older adults (PIDs) and drug-drug 
interactions (DDIs) (Paper IV), as well as prescribing in public and private nursing 
homes.  
A resident was classified as a medication user if his or her medication record 
indicated a regular sequence for its dosage. Others, including those whose medication 
records permitted administration of the drug as needed (pro re nata), were classified 
as non-users. Mini Nutritional Assessment (MNA) was used to assess residents’ 
nutritional status, Beers 2003 criteria to assess the use of PIDs, and the Swedish, 
Finnish, INteraction X-referencing database (SFINX) to evaluate their exposure to 
DDIs.  
Of all nursing home residents in Helsinki, 82% (n=1987) participated in studies on 
psychotropic drugs, laxatives, and potentially inappropriate drugs for the elderly as 
well as drug-drug interactions. Altogether 87% of the residents (n=2114) participated 
in this study assessing the use of vitamin D and calcium supplements. The residents’ 
mean age was 84 years, 81% were female, and 70% were diagnosed with dementia. 
The mean number of drugs was 7.9 per resident; 40% of the residents used ≥ 9 
drugs per day, and were thus exposed to polypharmacy. 
Of the residents, 80% received psychotropic medication, 43% received 
antipsychotic medication, and 45% used antidepressants. Anxiolytics were prescribed 
to 26%, and hypnotics to 28% of the residents. Of those residents diagnosed with 
dementia, 11% received antidementia drugs.  
More than half (55%) of the residents received laxatives regularly. In multivariate 
analysis, those factors associated with regular laxative use were advanced age, 
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immobility, poor nutritional status, chewing problems, Parkinson’s disease, and a high 
number of drugs. Eating snacks between meals was associated with lower risk for 
laxative use. 
Of all participants, 33% received vitamin D supplementation, 28% received 
calcium supplementation, and 20% received both vitamin D and calcium. The dosage 
of vitamin D was rather low: 21% received vitamin D 400 IU (10 µg) or more, and 
only 4% received 800 IU (20 µg) or more. In multivariate analysis, residents who 
received vitamin D supplementation enjoyed better nutritional status, ate snacks 
between meals, suffered no constipation, and received regular weight monitoring.  
Those residents receiving PIDs (34% of all residents) more often used 
psychotropic medication and were more often exposed to polypharmacy than 
residents receiving no PIDs. Residents receiving PIDs were less often diagnosed with 
dementia than were residents receiving no PIDs. The three most prevalent PIDs were 
short-acting benzodiazepine in greater dosages than recommended, hydroxyzine, and 
nitrofurantoin.  These three drugs accounted for nearly 77% of all PID use.  
Of all residents, less than 5% were susceptible to a clinically significant DDI. The 
most common DDIs were related to the use of potassium-sparing diuretics, 
carbamazepine, and codeine. Residents exposed to potential DDIs were younger, had 
more often suffered a previous stroke, more often used psychotropics, and were more 
often exposed to PIDs and polypharmacy than were residents not exposed to DDIs. 
Residents in private nursing homes were less often exposed to polypharmacy than 
were residents in public nursing homes.  
Long-term residents in nursing homes in Helsinki use, on average, nearly eight 
drugs daily. The use of psychotropic drugs in our study was notably more common 
than in international studies. The prevalence of laxatives equaled other prior 
international studies. Regardless of the known benefit and recommendation of vitamin 
D supplementation for elderly residing mostly indoors, the proportion of nursing home 
residents receiving vitamin D and calcium was surprisingly low. The use of PIDs was 
common among nursing home residents. PIDs increased the likelihood of DDIs. 
However, DDIs did not seem a major concern among the nursing home population. 





Ikääntyvät ihmiset sairastavat paljon ja käyttävät runsaasti lääkkeitä. Monilääkitys on 
yleistä erityisesti laitoksissa asuvien vanhusten keskuudessa. Toimintakyvyn ja 
aistitoimintojen heikkeneminen sekä ikääntymisen aiheuttamat muutokset 
farmakokinetiikassa ja farmakodynaamiikassa altistavat vanhukset lääkehoidon 
aiheuttamille haitoille. 
Tämä tutkimus on poikkileikkaus helsinkiläisten vanhainkotien yli 64-vuotiaiden 
pitkäaikaisasukkaiden lääkehoidosta ja siihen vaikuttavista tekijöistä. Tarkastelimme 
psyykelääkkeiden (osatyö I), laksatiivien (osatyö II), D-vitamiinin ja kalsiumin 
(osatyö III), sekä vanhuksille sopimattomien lääkkeiden (osatyö IV) käyttöä. 
Tarkastelimme myös lääkkeiden yhteisvaikutusten yleisyyttä (osatyö IV) sekä 
lääkkeiden käytön eroja julkisissa ja ostopalveluvanhainkodeissa.  
 Asukkaiden terveydentilaa ja lääkitystä koskevat tiedot kerättiin helmikuussa 
2003. Asukas luokiteltiin lääkkeen käyttäjäksi, jos hänen sairaskertomuksestaan 
ilmeni määräys lääkkeen säännölliseksi annosteluksi. Asukkaiden ravitsemustila 
arvioitiin Mini Nutritional Assessment-menetelmällä. Vanhuksille sopimattomien 
lääkkeiden käyttöä arvioitiin Beersin vuonna 2003 julkaistun vanhuksille 
sopimattomien lääkkeiden kriteeristön avulla ja lääkkeiden yhteisvaikutuksille 
altistumista arviointiin SFINX-interaktiotietokannan avulla.   
Psyykelääkkeiden, laksatiivien ja vanhuksille sopimattomien lääkkeiden käyttöä ja 
lääkkeiden yhteisvaikutuksille altistumista selvittäneisiin tutkimuksiin osallistui 82% 
(n=1987) helsinkiläisten vanhainkotien asukkaista. D-vitamiini- ja 
kalsiumvalmisteiden käytön tutkimukseen osallistui 87% (n=2114) asukkaista. 
Asukkaiden keski-ikä oli 84 vuotta, heistä 81% oli naisia ja 70%:lla oli 
dementiadiagnoosi. Asukkaiden keskimääräinen päivittäinen lääkemäärä oli lähes 8 
lääkettä ja 40% asukkaista käytti päivittäin yli yhdeksää lääkettä.  
Asukkaista 80% käytti psyykelääkkeitä. Antipsykootteja käytti 43% asukkaista ja 
45% asukkaista käytti mielialalääkkeitä. Rauhoittavia lääkkeitä käytti säännöllisesti 
26% ja unilääkkeitä 28% asukkaista. Dementiaa sairastavista asukkaista 11% käytti 
dementialääkitystä.  
Yli puolet asukkaista (55%) käytti laksatiiveja säännöllisesti. Monimuuttuja-
analyysissa niiden käyttöön liittyi korkea ikä, huono liikkumiskyky, huono 
ravitsemustila, puremisongelmat, Parkinsonin tauti ja suuri lääkemäärä. Välipalojen 
syönti liittyi vähäisempään laksatiivien käyttöön.   
D-vitamiinivalmistetta käytti 33% ja kalsiumvalmistetta 28% asukkaista. 
Yhtäaikaisesti D-vitamiini- ja kalsiumvalmistetta käytti 20% asukkaista. D-
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vitamiiniannokset olivat pieniä: 21% asukkaista sai D-vitamiinia tutkimuksen aikaisen 
suositusannoksen 10μg (400 IU) ja 4% sai D-vitamiinia 20μg (800 IU) tai enemmän. 
D-vitamiinia käyttäneillä asukkailla oli parempi ravitsemustila, he söivät useammin 
välipaloja, heillä oli harvemmin ummetusta ja heidän painoaan seurattiin useammin 
kuin asukkailla, jotka eivät käyttäneet D-vitamiinivalmisteita.  
Beersin vuoden 2003 kriteerien mukaan vanhuksille sopimattomia lääkkeitä käytti 
34% asukkaista. Niiden käyttäjät käyttivät useammin psyykelääkkeitä ja yli yhdeksää 
lääkettä päivittäin. He myös sairastivat harvemmin dementiaa kuin asukkaat, jotka 
eivät käyttäneet vanhuksille sopimattomia lääkkeitä. Yleisimmät sopimattomat 
lääkkeet olivat lyhytvaikutteiset bentsodiatsepiinit, joiden annostus oli suositusta 
suurempi, hydroksitsiini ja nitrofurantoiini. Näiden osuus kaikista vanhuksille 
sopimattomista lääkkeistä oli yhteensä lähes 77%. Lääkkeiden mahdolliselle 
yhteisvaikutukselle altistui alle 5% asukkaista. Keskeisimmät mahdollisiin 
yhteisvaikutuksiin liittyvät lääkkeet olivat kaliumia säästävät diureetit, 
karbamatsepiini ja kodeiini. Asukkaat, jotka altistuivat mahdolliselle lääkkeiden 
yhteisvaikutukselle olivat nuorempia, heillä oli useammin ollut aikaisempi 
aivoverenkiertohäiriö, he käyttivät useammin psyykelääkkeitä, vanhuksille 
sopimattomia lääkkeitä sekä yli yhdeksää lääkettä päivittäin verrattuna lääkkeiden 
yhteisvaikutuksille altistumattomiin asukkaisiin. Ostopalveluvanhainkotien asukkaat 
käyttivät harvemmin yli yhdeksää lääkettä päivittäin kuin julkisten vanhainkotien 
asukkaat.  
Helsinkiläisten vanhainkotien pitkäaikaishoidossa olevat asukkaat käyttävät 
keskimäärin lähes kahdeksaa lääkettä päivittäin. Psyykelääkkeiden käyttö on 
kansainvälisiin tutkimuksiin verrattuna erityisen yleistä. Laksatiivien käytön yleisyys 
ei eroa kansainvälisistä tutkimuksista.  Vaikka D-vitamiinin hyödyt ovat tiedossa ja 
sen käytöstä on olemassa kansallinen suositus,  yllättävän harvat vanhainkodin 
asukkaat saavat D-vitamiinia. Vanhuksille sopimattomien lääkkeiden käyttö on melko 
yleistä. Lääkkeiden yhteisvaikutukset eivät käytetyn mittarin valossa vaikuta olevan 





Prescribing for older patients is challenging. The prevalence of diseases increases 
with advancing age and causes extensive drug use. Impairments in cognitive, 
sensory, social and physical functioning, multimorbidity and comorbidities, as well as 
age-related changes in pharmacokinetics and pharmacodynamics that impair the 
functional reserve of multiple systems and organs, all add to the complexity of 
prescribing. Consequently, older people are at particular risk for adverse drug events.  
Drug therapy is an integral part of the care of older people. Optimizing drug 
prescribing for older adults is an important public health issue, especially in countries 
with a growing elderly population. Few randomized controlled trials include older 
multimorbid participants, and evidence-based guidelines recommending multiple drug 
regimens for the treatment of disorders common among older people are based on 
studies performed on younger individuals. In addition, the symptomatic relief of 
common conditions among older adults, such as pain and arthritis, increase the 
number of drugs used.    
Interindividual variation in health, disease, and functional abilities increases with 
age and complicates decision-making in prescribing. Although the number of fit, 
healthy older people is rising, the number of older people with limited physiological 
reserve, reduced ability to recover from stress, dysregulation in immune and 
inflammation mechanisms, comorbidities and polypharmacy is also rising. The frailest 
older people, who are no longer capable of dwelling at home or in sheltered living, are 




2 Review of the literature 
2.1 Physiological changes in aging 
Conventionally, the elderly have been defined most frequently by a chronological 
age of 65 years and older (Klotz 2009). However, the interindividual variability in 
health, disease, physiological responses, and disability – a phenomenon known as 
aged heterogeneity – increases substantially with aging, and the health status of the 
elderly varies more widely than does that of younger adults (Spinewine et al. 2007). 
Reduced homeostatic ability affects different regulatory systems in different 
individuals, which partly explains the increased interindividual variability (Mangoni & 
Jackson 2003). 
Aging results from cumulative local effects at the molecular, cellular and tissue 
levels. Aging can be defined as a time-related loss of functional units, the disruption 
of regulatory processes providing functional integration between cells and organs, and 
failure to maintain homeostasis under physical stress (Mangoni & Jackson 2003). 
Primary aging is an inevitable, irreversible process in which the body slowly 
deteriorates with time (McLean & Le Couteur 2004). Secondary aging is a faster 
process resulting from illnesses and immobility. Secondary aging can be decelerated 
through lifestyle changes, physical activity, proper care, and rehabilitation. Aging 
results in anatomical and functional changes that may lead to the decompensation of 
a relevant system when the change progresses beyond a certain threshold (Mangoni 
& Jackson 2003). Progressive impairments in the functional reserve of multiple organs 
may increase the susceptibility of older people to stress as well as affect drug 
metabolism and pharmacokinetics (Klotz 2009).  
2.1.1 Pharmacokinetic and pharmacodynamic changes  
Pharmacokinetics investigates drug absorption, distribution, metabolism, and 
excretion. Pharmacodynamics investigates drug effects and modes of action in the 
body. Aging affects both pharmacokinetics and pharmacodynamics.  
 
Pharmacokinetic changes in aging 
Aging affects gastric pH, gastrointestinal circulation, motility, and mucous 
membranes, but the overall effect in drug absorption from the intestines is clinically 
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insignificant (Turnheim 2004) (Table 1). Transdermal and subcutaneous absorption, 
as well as drug absorption from muscular tissue, may diminish due to reduced blood 
perfusion (Turnheim 2004). However, the evidence of age differences in 
percutaneous, transbronchial, and rectal routes of administration remains insufficient 
(Schwartz 2007). 
The amount of metabolically active tissue decreases, and the relative amount of body 
fat increases; consequently, the lean body mass/body fat ratio decreases (Morley 
1997). The distribution volume of hydrophilic drugs such as digoxin and furosemide 
decreases, and the use of diuretics may further reduce the amount of extracellular 
water (Turnheim 2004). The proportion of body fat and, consequently, the relative 
distribution volume of lipid-soluble drugs such as diazepam increases, thus prolonging 
their half-life and action (Turnheim 2004). The drug molecule-binding plasma albumin 
decreases, and the free fraction of the drug increases. After absorption, the blood 
circulation transports the drug molecules through the portal vein into the liver. The 
transformation of the drug molecules at this stage is known as first-pass metabolism.  
The hepar blood flow declines with aging, so drugs that the liver clears from the 
circulation display an age-dependent decrease in metabolic clearance (McLean & Le 
Couteur 2004). The activity of cytochrome P450 enzymes, however, remains unaltered, 
at least in vitro, and in general, the interindividual variation in metabolic drug 
clearance by CYP enzymes exceeds the decline due to aging (Turnheim 2004). 
An important pharmacokinetic change in aging is reduced renal function, 
glomerular filtration rate, tubular secretion, and renal blood flow (Mitchell et al. 
2009). The decline in drug elimination may lead to elevated drug serum 
concentrations. Renal mass and the number of nephrons also decrease, and renal 
excretatory function declines with advancing age in healthy individuals as well. Serum 
creatinine may remain within normal limits despite a reduction in creatinine clearance 
due to reduced muscle mass and creatinine production (Hutchison & O’Brien 2007). 
The Cockgroft-Gault equation (Cockcroft & Gault 1976) is the most widely used 
formula for estimating creatinine clearance (Hutchison & O’Brien 2007). The equation 
incorporates serum creatinine, age, gender, and weight to estimate creatinine 
clearance, and can thus serve to estimate creatinine clearance in older people in order 
to adjust the maintenance dose of renally excreted drugs with narrow therapeutic 
indices (Turnheim 2004). However, the Cockgroft-Gault equation underpredicts renal 
function for patients weighing less than their ideal body weight and overpredicts renal 




Table 1. Age-related pharmacokinetic changes (adapted from Klotz 2009, Mangoni & 




Gastric secretion ↓ 
Gastric emptying ↓ 
Splanchnic blood flow ↓ 
Absorption surface ↓ 
Gastrointestinal motility ↓ 
 
No clinically significant change in absorption 
Body weight ↓ 
Body fat 25-30% ↑ 
Lean body mass 25-30% ↓ 
Plasma volume ↓ 
Extracellular body fluid ↓ 
Total body water 25-30% ↓ 
 
Increased volume of distribution, prolonged half-
life, extended clearance of lipophilic drugs and 
elevated plasma concentration of hydrophilic drugs  
Serum albumin ↓ 
 
 
α1-acid glycoprotein ↑ 
 
Increased free fraction in plasma of a few highly 
protein-bound acidic drugs (e.g. warfarin)  
 
Decreased free fraction in plasma of a few basic 
drugs (e.g. propranolol) 
 
Hepatic mass 20-40% ↓ 
Hepatic blood flow 20-50% ↓ 
 
 
First-pass metabolism can be less effective, thus 
raising bioavailability. Some drugs may slightly 
impair phase I metabolism through the 
cytochrome P450 enzyme system. No significant 
change occurred in phase II metabolism. 
Renal mass 20-30% ↓ 
Glomeruli 20-30% ↓ 
Renal blood flow ↓ 
Filtration fraction ↓ 
Tubular secretion ↓ 
Glomerular filtration rate  
10% ↓ per decade 
In the absence of disease, kidney function 
decreases less than previously thought. Aging can 
impair the renal clearance of drugs, which has a 
lower prevalence in women than in men. 
 
 
Pharmacodynamic changes in aging 
Age-related changes in pharmacodynamics result in changes in the effector 
system: a decrease in the number of drug receptors, changes in receptor affinity, 
signal transduction, and end-organ response, as well as reduced counter-regulatory 
physiological and homeostatic processes that aim to preserve the original functional 
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equilibrium (Turnheim 2004, Mitchell et al. 2009, Hutchison & O’Brien 2007). 
Pharmacodynamic changes in old age include alterations in calcium channels, for 
example, and a reduction in the response of beta-adrenergic receptors, and 
heightened sensitivity to the sedating effects of certain medications as well as 
postural hypotension (McLean & Le Couteur 2004, Hilmer et al. 2007b) (Table 2). Risk 
for experiencing ortostatic hypotension increases due to reduced arterial compliance 
and baroreceptor reflex response (Hutchison & O’Brien 2007). Drugs that can 
exacerbate ortostatic hypotension include tricyclic antidepressants, antipsychotics, 
diuretics (especially loop diuretics), angiotensin-converting enzyme inhibitors, direct 
vasodilatators, and opioids (Hutchison & O’Brien 2007). Other cardiovascular 
pharmacodynamic changes include increased risk for drug-induced QT interval 
prolongation and torsades de pointes, as well as the reduced number and 
responsiveness of muscarinic receptors (Hutchison & O’Brien 2007).  
A decline in fluid and electrolyte homeostatic mechanisms exposes older people to 
adverse drug effects such as hyponatremia, inappropriate secretion of antidiuretic 
hormone, hyperkalemia, and dehydration (Hutchison & O’Brien 2007). Alterations in 
the number of neurons and receptors in the central nervous system, changes in the 
metabolism of neurotransmitters, and the greater permeability of the blood-brain 
barrier predispose the elderly to adverse drug reactions from central nervous system 
drugs. The elderly experience heightened sensitivity to benzodiazepines, which may 
cause ataxia, sedation and cognitive impairment, as well as to the anticholinergic 
effects of drugs (Hutchison & O’Brien 2007). The numbers of dopaminergic neurons 
and dopamine D2 receptors decrease with age, thus increasing the risk for 
extrapyramidal adverse drug reactions (Mitchell et al. 2009). Changes in patient 
medical status over time may cause long-term drug therapy to become unsafe or 
ineffective (Turnheim 2004). 
2.1.2 Nutrition and aging 
Malnutrition results from insufficient intake of macronutrients (protein-energy 
malnutrition, vitamin and mineral deficiency), excessive intake of macronutrients 
(obesity), or excessive amounts of inappropriate substances such as alcohol (Omran 
& Morley 2000). The prevalence of undernutrition, often called malnutrition, among 
elderly home-dwellers is 1% to 15%, among the institutionalized elderly 21% to 60%, 




Table 2. Selected age-related pharmacodynamic changes (modified from Mangoni & 
Jackson 2003, McLean & Le Couteur 2004) 
Drug Pharmacodynamic effect Age-related change 
Adenosine Heart-rate response       ↔ 
Diazepam Sedation, postural sway ↑ 




Diphenhydramine Postural sway ↔ 
Enalapril Angiotensin-converting enzyme inhibition ↔ 
Flunitrazepam Sedation ↑ 
Furosemide Peak diuretic response ↓ 
Heparin Anticoagulant effect ↔ 
Isoprenaline Chronotropic effect ↓ 
Midazolam Sedation ↑ 




Phenylephrine α1-adrenergic responsiveness ↔ 
Propranolol Antagonism of chronotropic effects of 
isoprenaline 
↓ 
Salbutamol Bronchodilatation ↓ 
Scopolamine Cognitive function ↓ 
Temazepam Postural sway ↑ 




Warfarin Anticoagulant effect ↑ 
 
     One’s energy expenditure and need for energy declines with advancing age, but 
one’s need for nutrients is the same as or even greater than at a younger age 
(Russell 2000). Dryness of the mouth, as well as dental and swallowing problems, 
complicate chewing and swallowing, which may result in declining nutritional status 
(Soini et al. 2006). Illnesses, such as osteoarthritis and cardiovascular diseases, may 
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affect mobility, and decreasing mobility decreases appetite (Pitkälä & Strandberg 
2003). Between the ages of 70 and 90, older people’s energy intake declines by 20%, 
which accelerates the frailty process, sarcopenia and inflammation (Moreiras et al. 
1996, Morley 2001, Wakimoto & Block 2001). With advancing age, one’s sense of 
hunger and thirst weakens, which may, along with cognitive impairment, contribute to 
the onset of malnutrition (Naitoh & Burrell 1998). Reduced eating affects one’s intake 
of beneficial nutrients, and the quality of one’s diet becomes difficult to maintain 
(Ruiz-Lopez et al. 2003). Consequently, dietary guidelines for elderly people should 
emphasize nutrient-dense foods (Foote et al. 2000). 
Aging reduces one’s ability to regulate energy intake (Roberts & Rosenberg 2006). 
An older person experiencing energy deficit due to acute disease, for example, 
struggles to return to his or her preceding diet and to regain the lost weight (Roberts 
et al. 1994).  
Malnutrition is especially common among nursing home residents (Saletti et al. 
2000, Guigoz et al. 2002). The prevalence of malnutrition among institutionalized 
residents is about 21% to 40% (Guigoz 2006, Saletti et al. 2000, Suominen et al. 
2005). Patients with dementia are at particularly high risk for malnutrition (Cronin-
Stubbs et al. 1997). A Finnish study reported a daily energy intake of 1205 and 1230 
kcal among 44 female residents in dementia wards, which represents only 66% to 
77% of the recommended daily energy intake for females aged ≥ 75 years (Suominen 
2007). The Finnish National Nutrition Council has published its first guidelines for the 
nutrition and nutritional care of older people in March 2010 (Suominen et al. 2010).  
Nutritional status significantly affects drug metabolism (Turnheim 2004). 
Advanced malnutrition may lower the plasma albumin concentration, which raises the 
concentration of free drug molecules in circulation, and thus may fortify the effect of 
the drug (Javaid & Morley 2000). Dehydration, loss of total body water, and decrease 
of lean body mass may lead to a higher concentration of water-soluble drugs and a 
longer half-life of lipid-soluble drugs (Javaid & Morley 2000). On the other hand, 
drugs can also affect appetite and nutrition. Drugs with anticholinergic properties can 
cause dryness of the mouth and slow gastrointestinal peristalsis. Constipation-
inducing drugs, such as opioids, can affect appetite, and thus increase the risk for 
malnutrition. Some drugs, such as anticholinesterases (AChEs), selective serotonin 
reuptake inhibitors (SSRIs) and macrolides, may cause diarrhea and nausea 






 Assessment of nutritional status 
 
Good nutritional status in old age contributes to health and the ability to recover 
from illness. Early detection of malnutrition and the risk for undernutrition are 
essential for improving the care of older people (Reynish & Vellas 2001). The full 
assessment of elderly people’s nutritional status includes several biochemical and 
anthropometric measurements, but performing a full assessment for all nursing home 
residents is neither practical nor cost-effective (Reynish & Vellas 2001). Screening for 
nutritional status is a rapid and simple process performed by health care teams, 
whereas a full nutritional assessment is a detailed examination that involves several 
measures ranging from subjective assessment to objective measurements of 
metabolic, nutritional or functional variables performed by an expert clinician, 
nutrition nurse or dietician (Green & Watson 2006, Kondrup et al. 2003). Regular 
weight monitoring should be implemented as a surveillance measure of nutritional 
status (Cowan et al. 2004), and all patients should be screened on admission to 
hospitals or other institutions (Kondrup et al. 2003). 
A meta-analysis taking into account 21 different nutritional screening and 
assessment tools for older adults, proved that the Mini Nutritional Assessment (MNA), 
was the most extensively evaluated tool for screening the nutritional status of the frail 
elderly (Green & Watson 2006). MNA is reliable and well validated, involves no 
laboratory analyses, and is suitable for screening large populations (Omran & Morley 
2000, Guigoz 2006, Guigoz et al. 2002). MNA includes 18 variables: anthropometric 
measurements (BMI, weight loss, arm and calf circumferences), general health 
assessment (dwelling place, medication, mobility, acute disease or stress, signs of 
depression or dementia, skin ulcers), short dietary assessment (number of meals, 
protein, vegetable and fluid intake, mode of feeding), and subjective assessment (self 
perception of health and nutrition) (Vellas et al. 1999 and 2006). Nutritional status is 
assessed in two steps. The MNA short form serves to screen nutritional status, and if 
a concern about possible malnutrition arises, the complete version of MNA follows. 
MNA takes less than 15 minutes to complete. The complete version of MNA provides a 
maximum of 30 points and distinguishes individuals as having adequate nutritional 
status (≥ 24 points), at risk for malnutrition (17-23.5 points), and protein-calorie 
malnutrition (< 17 points) (Vellas et al. 1999). Usually, patients with a score of 17.5 
to 23.5 points have not yet begun to lose weight and show no low plasma albumin 
levels, but often have a lower protein-calorie intake than recommended (Vellas et al. 
2006). MNA is likely to detect the risk for and early stages of undernutrition, since the 
method assesses physical and mental aspects of health that often affect the 
nutritional status of the elderly (Kondrup et al. 2003). 
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2.2 Drug use among the elderly  
2.2.1 Epidemiology of drug use 
Elderly people have multiple morbidities and symptoms, and thus use a 
considerable number of medications. Two thirds of people aged ≥65 years and over 
90% of people aged ≥80 years take medications regularly (Giron et al. 1999).  
In Lieto, a municipality in south-western Finland, 78% of the home-dwelling 
elderly aged ≥ 64 years used at least one prescription drug in 1990-1991; in 1998-
1999, this figure rose to 88% (Linjakumpu et al. 2002a). The mean number of 
prescription medications rose from 3.1 to 3.8 (Linjakumpu et al. 2002b). In Kuopio, a 
city in eastern Finland, 90% of those aged ≥75 years used regular medication in 1998 
and 97% in 2003 (Jyrkka et al. 2006). In both samples, people living in institutions 
took significantly more medication regularly and as needed than did community-
dwellers: the numbers of medications institutionalized people took were 4.7 
(regularly) and 2.8 (as needed) in 1998, and 7.2 (regularly) and 3.7 (as needed) in 
2003. Among community-dwellers, the figures were 4.0 (regularly) and 2.3 (as 
needed) in 1998, and 5.4 (regularly) and 1.7 (as needed) in 2003 (Jyrkka et al. 
2006). 
In the US, people aged 65 or older (12% of the population) are prescribed one 
third of all drugs and consume more than half of all over-the-counter medications 
(Ostrom et al. 1985). Home-dwelling older people consume on average four to five 
medications (Giron et al. 1999), whereas those dwelling in nursing homes and 
geriatric wards consume on average eight to ten medications (Pitkala et al. 2004, 
Socialstyrelsen 2004). Information about drug use among the home-dwelling elderly 
may be less reliable than among institutionalized older people. In Finland, register 
data are available only for prescription medications, not for over-the-counter drugs. 
Moreover, whether or how a home-dweller actually consumes the medications 
remains uncertain. 
2.2.2 Psychotropic medication 
Epidemiology of psychotropic medication use 
 
Psychotropic drugs are classified as antipsychotics (N05A), antidepressants 
(N06A), anxiolytics (N05B), hypnotics (N05C), and anti-dementia drugs (N06D) (ATC 
DDD 2009). The use of these medications is very common among the elderly.  
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In Lieto, the prevalence of psychotropic drugs among the home-dwelling elderly 
aged ≥ 64 years was 24% in 1990-1991 and 27% in 1998-1999 (Linjakumpu et al. 
2002a). In both samples, hypnotics/sedatives were the most prevalent psychotropic 
drugs (Linjakumpu et al. 2002a). In the Swedish Kungsholmen project, which 
comprised Stockholm-dwelling elderly aged ≥ 81 years, the institutionalized 
participants used more psychotropic drugs than did the non-institutionalized in 1987-
1989 (60.3% vs. 38.5%) and in 1994-1996 (71.1% vs. 36.2%) (Giron et al. 2001).  
The Minimum Data Set, a standardized, clinically based assessment instrument 
that collects information on each nursing home resident’s demographic, functional, 
medical, psychological, and cognitive status (Liperoti et al. 2003), has provided some 
information on psychotropic drug use in nursing homes in Finland (Noro et al. 2005). 
Studies reporting the prevalence of psychotropic drug use among nursing home 
residents are listed in Table 3.  
 
Indications of psychotropic medications among the elderly 
 
Dementia, with its psychological and behavioral symptoms, is the most common 
reason for admittance to institutional care (Phillips & Diwan 2003). Antipsychotics 
often serve to treat psychotic symptoms as well as to control the behavioral and 
psychological symptoms of dementia (Avorn & Gurwitz 1995).  
The Nursing Home Reform Act, embedded within the Omnibus Budget 
Reconciliation Act 1987 (OBRA 87), was enacted to restrict psychotropic drug use in 
long-term care in the US (McGrath & Jackson 1996, Snowden & Roy-Byrne 1998, 
Hughes & Lapane 2005). This legislation states that each resident’s drug regimen 
must not include unnecessary drugs (defined as drugs used in excess dose or 
duration, or without adequate monitoring or indication) or adverse reactions that 
suggest the drug should be discontinued or the dosage lowered (Hughes & Lapane 
2005).  
The OBRA 87 states that residents have the right to be free of psychotropics 
administered without proper indication. Disallowed indications for antipsychotic drug 
use include wandering, restlessness, anxiety, and uncooperativeness. Antipsychotic 
drug use is permitted if the patient has schizophrenia, schizoaffective disorder, or 
delusional disorder. 
According to the OBRA 87, a consultant pharmacist should evaluate a patient’s 
drug regimen on a monthly or quarterly basis (Hughes & Lapane 2005). In 1999, the 
Beers criteria for potentially inappropriate medication use and a set of quality 
indicators were incorporated within the OBRA 87 (Hughes & Lapane 2005). In 2004, 5 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































antipsychotic use in the absence of psychotic or related conditions, ii) the 
prevalence of any anxiolytic/hypnotic use, iii) the prevalence of hypnotic use more 
than twice in the past week, iv) the prevalence of symptoms of depression, and v) the 
prevalence of depression with no antidepressants. 
The psychotropic drug administrative initiative has reduced antipsychotic 
prescribing in the US (Hughes & Lapane 2005). Finnish authors suggest evaluating an 
older patient’s drug regimen when necessary and at least once a year (Hartikainen & 
Seppälä 2007). 
2.2.3 Laxatives 
Constipation is one of the most common complaints among the frail elderly. More 
than half of nursing home residents have constipation (Phillips et al. 2001). The Rome 
III consensus criteria define functional constipation as a functional bowel disorder 
with persistently difficult, infrequent, or seemingly incomplete defecation which does 
not meet irritable bowel syndrome criteria (Longstreth et al. 2006). Patients 
complaining of constipation may suffer from colonic inertia or anorectal dyssynergia, 
but most patients experience normal colonic transit and anorectal function 
(Longstreth et al. 2006). Even though the incidence of constipation increases with 
age, healthy elderly do not necessarily suffer from constipation, and constipation 
should not be considered unavoidable due to advancing age.  
Constipation is the only indication for laxatives; consequently, they may serve as a 
marker for constipation (van Dijk et al. 1998, Harari et al. 1995, Monane et al. 1993). 
Laxative consumption increases with age, and 50% to 74% of nursing home residents 
regularly receive laxatives (van Dijk et al. 2000, Phillips et al. 2001, van Dijk et al. 
1998, Harari et al. 1995, Monane et al. 1993, Brocklehurst et al. 1999, Kinnunen 
1991). Despite their extensive use, a meta-analysis reported insufficient evidence of 
the efficacy of laxatives over placebo in chronic constipation due to lack of published 
research (Jones et al. 2002). In addition, many consider the long-term use of some 
bowel-stimulating laxatives inappropriate for the elderly (Fick et al. 2003).  
Studies on older nursing home residents have reported a significant association 
between constipation and Caucasian ethnicity, low fluid intake, pneumonia, 
Parkinson’s disease, allergies, immobility, arthritis, polypharmacy, new medications, 
dementia, hypothyroidism, and hypertension (Robson et al. 2000) as well as between 
laxative use and immobility, Parkinson’s disease, and diabetes mellitus (Harari et al. 
1995).  In testing the effectiveness of a particular medication, numerous clinical drug 
trials have reported constipation as a side effect. Even so, large-scale epidemiological 
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studies describing the associations of drugs and constipation are nevertheless scarce. 
Studies on older nursing home residents have shown that iron supplements (van Dijk 
et al. 1998, Harari et al. 1995), calcium channel blockers (Harari et al. 1995), 
verapamil (van Dijk et al. 1998), calcium supplements (van Dijk et al. 1998), 
anticholinergic neuroleptics (Monane et al. 1993), and anticholinergic antidepressants 
(Harari et al. 1995, Monane et al. 1993) are associated with laxative use.   
Nurses play a significant role in the assessment and treatment of constipation. The 
staffing costs account for 70% of total drug costs in constipation care (Pekmezaris et 
al. 2003).  
2.2.4 Vitamin D and calcium 
Fractures in the elderly are associated with two risk factors: the loss of bone mass 
due to osteoporosis and increased susceptibility to falls (Meunier et al. 1994, Boonen 
et al. 2006). The annual rate of falling among home-dwelling people aged ≥ 65 years 
is 0.3 to 1.6 per person; 5% of these falls induce a fracture or require hospitalization 
(Rubenstein 2006). For nursing home-dwellers, the annual rate is much higher: 0.6 to 
3.6 per bed; 10% to 25% of the falls result in fracture or laceration (Rubenstein 
2006).  
A growing body of evidence shows that vitamin D and calcium play a role in 
preventing falls and fractures (Meunier et al. 1994, Bischoff-Ferrari et al. 2005, 
Bischoff-Ferrari et al. 2004a, Bischoff-Ferrari et al. 2004b). Vitamin D and calcium 
benefit calcium homeostasis and bone mineral density, and vitamin D improves 
musculoskeletal function, thus reducing the risk from falls (Boonen et al. 2006, 
Bischoff-Ferrari et al. 2004b). 
Vitamin D is a derivate of cholesterol. Cholecalciferol (vitamin D3) is synthesized in 
the skin in a photochemical reaction driven by ultraviolet radiation. Ergocalciferol 
(vitamin D2) is of vegetable origin. Both vitamin D3 and D2 can be obtained from food 
and vitamin supplements. Ergocalciferol and cholecalciferol are inactive; they must be 
first hydrolyzed into 25-hydroycholecalciferol in the liver and then into the active 
1,25-dihydroxycholecalciferol in the kidneys (Pelkonen & Ruskoaho 2003).  
In both active and inactive ambulatory persons aged ≥ 60 years, serum 25-
hydroxycholecalsiferol concentrations of 40 to 90 nmol/l were associated with better 
musculoskeletal function in the lower extremities than were concentrations of < 40 
nmol/l (Bischoff-Ferrari et al. 2004b). Calcium absorption seems to be maximized in 
serum 25-hydroxycholecalsiferol concentrations of > 80 nmol/l (Heaney 2004). In a 
US study of healthy adult men, the mean serum 25-hydroxycholecalsiferol 
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concentration in autumn was 70 nmol/l. The dose of vitamin D supplementation 
needed to sustain this serum 25-hydroxycholecalsiferol concentration during 
wintertime was 500 IU (12.5 µg) daily (Heaney et al. 2003). Elderly people who live 
in the northern latitudes and in institutions, and thus spend much of their days 
indoors, are at particular risk for low serum 25-hydroxycholecalsiferol concentrations. 
In addition, even in the presence of solar radiation, the cutaneous intake of 
cholecalciferol decreases with age (Heaney 2004). 
A meta-analysis of 12 trials found that oral cholecalsiferol (vitamin D3) in a daily 
dose of 700-800 IU (17.5-20 µg) or intermittent doses of 100 000 IU (2500 µg) every 
four months, with or without calcium, significantly reduced both hip and non-vertebral 
fractures (Bischoff-Ferrari et al. 2005). No significant benefit was observed for a daily 
dose of 400 IU (10 µg) of oral cholecalsiferol (Bischoff-Ferrari et al. 2005); other 
studies confirm these findings (Bischoff-Ferrari & Dawson-Hughes 2007, Venning 
2005, Broe et al. 2007). In a meta-analysis of five randomized controlled trials 
involving 1237 elderly participants, vitamin D in a daily dose of 800 IU (20 µg) or 
more reduced falling by 22% compared with patients receiving calcium or placebo; 
the number treated was 15 (Bischoff-Ferrari et al. 2004a).   
UV light exposure, food fortification, and supplements can contribute to the 
prevention of vitamin D deficiency. Vitamin D and calcium are an integral part of 
treatment for patients with osteoporosis, and are recommended for all elderly living in 
institutions. Vitamin D and calcium supplements are useful for older people at risk for 
low calcium intake, lacking exposure to sunlight, with low femoral bone density, a 
high serum parathyroid hormone concentration, a low serum 25-hydroxyvitamin D 
concentration, and a previous history of falls (Meunier et al. 1994). In the US, 32% of 
female nursing home residents received vitamin D supplements (Gupta & Aronow 
2003). In another US study, vitamin D was administered to 9% of nursing home 
residents, and calcium to 12% (Kamel 2004). 
The Finnish National Nutrition Council updated its recommendations concerning 
vitamin D intake in March 2010. They currently recommend supplementation in a 
daily dose of 800 IU (20µg) for older and institutionalized people (Suominen at al. 
2010). The former recommendation was daily dose of 400 IU (10 µg). The Finnish 
Current Care Guideline for osteoporosis recommends vitamin D in a daily dose of 700 
to 800 IU (17.5-20 µg) along with a calcium supplement (Current Care Guidelines). 
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2.3 Appropriate and inappropriate prescribing  
Quality of care, including prescribing, can be defined as the degree to which health 
services for individuals and populations increase the likelihood of desired health 
outcomes and are consistent with current professional knowledge (Lohr & Schroeder 
1990).  
The Oxford English Dictionary defines appropriate as suitable or proper to or for a 
particular purpose. Buetow et al. suggest that appropriate prescribing is an outcome 
of a process of decision-making that maximizes net individual health gains within 
society’s available resources (Buetow et al. 1997). They wish to differentiate the 
rationale of prescribing from the appropriateness of prescribing, and suggest that 
rationalism of prescribing refers to the prescribing process and appropriateness to its 
outcome. Thus, prescribing may be rational, but inappropriate when correct reasoning 
leads to a poor outcome due to, for example, inadequate information or 
communication problems. Moreover, the prescribing process may be irrational, but 
lead to an appropriate outcome (Buetow et al. 1997). The authors suggest that the 
suitable allocation of resources is a prerequisite of appropriate prescribing, and the 
objective is a balance between maximizing patient welfare and distributing resources 
according to need (Buetow et al. 1997). More simply, appropriate prescribing implies 
that the quality of prescribing is what should be achieved in practice (Spinewine et al. 
2007). The appropriateness of prescribing can also be assessed with following 
criteria: i) what the patient wants; ii) scientific rationalism, including clinical 
pharmacology of the drug; and iii) the general good (Spinewine et al. 2007). 
Health care quality problems, including prescribing quality problems, may be 
classified as underuse, overuse, and misuse (Chassin & Galvin 1998) (Figure 1). 
Underuse is a failure to provide a service, in this case a medication, when it would 
have produced a favorable outcome for a patient. Overuse is providing a medication 
under circumstances in which the potential for harm exceeds the potential benefit. 
Misuse is selecting an appropriate medication, but prescribing it inappropriately 
(Chassin & Galvin 1998).  
Inappropriate prescribing can cause substantial morbidity and represents a clinical 
and economic burden to patients and society (Gurwitz et al. 1990, Hanlon et al. 
2001); inappropriate prescribing in elderly people has therefore become an essential 
public health issue worldwide (Spinewine et al. 2007). Reducing overuse and misuse 
improves the quality of care by sparing patients unnecessary risk and complications 
and reducing costs. Although solving underuse problems improves quality, it may 
increase costs (Chassin & Galvin 1998). Whether the costs actually rise, however, 
depends on the intervention and the time scale.   
 27
Evidence-based treatment of multimorbidities necessitates the use of multiple 
drugs; however, age-related factors predispose patients to adverse drug effects 
(ADEs) as well as to drug-drug interactions (DDIs). Among nursing home residents, 
impairments in cognitive, sensory, social and physical functioning, comorbidities, and 
age-related changes in pharmacokinetics and pharmacodynamics all contribute to the 
complexity of prescribing. 
 
Figure 1. Terminology of prescribing (adapted from Chassin & Galvin 1998 and 
Hemminki & Turakka 1977). 
2.3.1 Polypharmacy 
Polypharmacy is commonly defined as the use of multiple medications or the use 
of a medication for which there is no indication (Bushardt et al. 2008). In US nursing 
homes, the suggested criterion for polypharmacy is the daily consumption of ≥ 9 
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drugs (Hanlon et al. 2001). Other definitions in current use include minor 
polypharmacy (2-4 drugs daily) and major polypharmacy (≥ 5 drugs daily) (Bjerrum 
et al. 1997, Thomas et al. 1999), as well as excessive polypharmacy (≥ 10 drugs 
daily) (Jyrkka et al. 2006 and 2009). Some studies define polypharmacy as the long-
term use of two or more medications for at least 60 days per three-month period 
(Veehof et al. 1999 and 2000). Polymedicine means the use of multiple medications 
for the treatment of multiple comorbid conditions (Monane et al. 1997). 
Risk factors for polypharmacy include old age, comorbidity, poor self-rated health, 
recent hospitalization, female gender, low educational attainment, depression, 
multiple prescribers and prescriber characteristics (Linjakumpu et al. 2002b, Thomas 
et al. 1999, Jyrkka et al. 2009, Haider et al. 2009). In a study on polypharmacy 
among men aged 56-75 years in South Wales, 9% of the participants used ≥ 5 drugs 
per day; factors associated with the use of ≥ 5 drugs included increasing age, lower 
social class, unemployment, smoking, and obesity (Thomas et al. 1999). In Lieto, the 
use of ≥ 5 drugs daily among the home-dwelling elderly rose from 19% in 1990-1991 
to 25% in 1998-1999 (Linjakumpu et al. 2002b). In the Kuopio 75+ cross-sectional 
study of the home-dwelling elderly, the factors associated with the use of ≥ 10 drugs 
daily (including regular and as-needed medications) were age ≥ 85 years, female 
gender, moderate or poor self-reported health, diabetes mellitus, depression, pain, 
heart disease, and obstructive pulmonary disease (Jyrkka et al. 2009). In a 
prospective Kuopio 75+ study, which also included the institutionalized participants, 
the prevalence of participants consuming ≥ 5 drugs daily rose from 54% in 1998 to 
67% in 2003, and the prevalence of participants consuming ≥ 10 drugs daily rose 
from 19% in 1998 to 28% in 2003 (Jyrkka et al. 2006). 
Most clinical care guidelines fail to take into account multimorbidities, and strict 
adherence to guidelines in prescribing for older patients with multiple comorbidities 
may result in polypharmacy (Boyd et al. 2005) and thus diminish the quality of care 
among the elderly. The possible harmful effects of polypharmacy include adverse drug 
effects, drug-drug interactions, higher costs, poor patient compliance with medication 
administration, higher incidence of nursing home placement, errors in the 
administration of drugs, and the unintentional prescribing of additional drugs for the 
adverse effects of other drugs, also known as the prescribing cascade (Hilmer et al. 
2007b, Thomas et al. 1999, Satish et al. 1996). 
Some views support the use of multiple drugs. Several studies show that the 
elderly need drugs including preventive medications and benefit from them, but often 
go undertreated (Gurwitz 2004, Sloane et al. 2004, Rochon & Gurwitz 1995 and 1999, 
Ebrahim 2002). Some authors have suggested that the intention to reduce the use of 
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drugs among the elderly should not be the only aim in treatment, and polypharmacy 
may prove beneficial in controling many diseases among the elderly (Gurwitz 2004, 
Rochon & Gurwitz 1995). In many diseases, the use of multiple drugs in treatment 
has proved more effective than using only one or two drugs (Gurwitz 2004). 
2.3.2 Potentially inappropriate drugs in the elderly 
In 1991, Beers et al. published explicit criteria regarding potentially inappropriate 
drugs (PIDs) among older nursing home residents (Beers et al. 1991). The criteria 
were created by a US panel of experts in geriatric care, clinical pharmacology, and 
psychopharmacology using a modified Delphi technique to reach consensus. The 
criteria were updated in 1997 for all older people (Beers 1997), and the latest version 
was published in 2003 (Fick et al. 2003) (Table 4). These criteria consider a drug 
inappropriate for older adults if evidence of its efficacy is insufficient, if the potential 
adverse drug effects outweigh the benefits, or if a safer alternative exists. The latest 
versions also include criteria for drugs that should be avoided in older adults with 
certain diagnoses or conditions (i.e. drug-disease interactions). The Beers criteria 
have been more widely used than other criteria (McLeod et al. 1997, Naugler et al. 
2000) to describe inappropriate prescribing in older adults, although difficulties in 
generalizing explicit criteria from one country to another do exist (Spinewine et al. 
2007). 
The prevalence of PIDs among elderly home-dwellers in Helsinki was 13% in 
1998-1999 (Pitkala et al. 2002). The most common PIDs in this population include 
dipyridamole, long-acting benzodiazepines, amitriptyline, ergot mesyloids, muscle 
relaxants, and meprobamate. Moreover, the use of drugs considered inappropriate 
with regard to certain diagnoses or conditions was common (Pitkala et al. 2002).  
In a US study of nearly 17 000 community-dwelling elderly, 41% received one PID 
(according to the Beers 2003 criteria), and 14% received two or more PIDs (Fick et 
al. 2008). The most common PIDs in this population included estrogen, 
propoxyphene, and short-acting benzodiazepine in greater doses than recommended 
(Fick et al. 2008).  
A multicenter study that included eight countries across Europe combined the 
Beers 1997 and 2003 criteria and the McLeod criteria to assess PID use among elderly 
home care patients (Fialova et al. 2005). Of all the 2707 participants, 20% used at 
least one PID (according to the combined criteria), ranging from 6% in Denmark to 
41% in the Czech Republic. 
 30
Table 4. PIDs independent of diagnoses and conditions (modified from Fick et al. 
2003)  
Potentially inappropriate drug Concern 
A02BA01 cimetidine Central nervous system ADRs including confusion 
Gastrointestinal antispasmodic drugs:  
A03AA07 dicyclomine (dicycloverine),  
A03BA03 hyoscyamine,  
A03AB05 propantheline,  
A03B belladonna alkaloids,  
A03CA02 clidinium-chlordiazepoxide 
Anticholinergic ADRs, uncertain effectiveness 
A04 trimethobenzamide  Ineffective, extrapyramidal ADRs 
A06AA01 mineral oil Aspiration, ADRs 
Stimulant laxatives in long-term use 
without the co-administration of 
opiates:  
A06AB02 bisacodyl  
A06AB07 cascara sagrada 
A06AB05 castor oil 
Bowel dysfunction 
A10BB02 chlorpropamide Prolonged hypoglycemia 
B01AC05 ticlopidine  No better than acetylsalicylic acid, but more toxic 
B01AC07 short-acting dipyridamole  Orthostatic hypotension 
B03AA07 ferrous sulphate > 325 
mg/day 
Constipation in high doses 
C01AA05 digoxin > 0.125 mg/day 
(except when treating atrial 
arrhythmias) 
Reduced renal clearance may lead to higher risk for toxic 
effects 
C01BA03 disopyramide Negative inotrope, heart failure, anticholinergic ADRs 
C01BD01 amiodarone QT interval problems, torsades de pointes, ineffective 
C02AA02 reserpine > 0.25 mg Depression, impotence, sedation, orthostatic hypotension 
C02AB methyldopa and comb. Bradycardia, may exacerbate depression 
C02AC01 clonidine Orthostatic hypotension, central nervous system ADRs 
C02CA04 doxazosin Hypotension, dry mouth, urinary problems 
C02CC02 guanethidine, guanadrel Orthostatic hypotension 
C03CC01 etacrynic acid Hypotension, fluid imbalances 
C04AA01 isoxsuprine Uncertain or lack of efficacy 
C04AE01 ergot mesyloids 
C04AX01 cyclandelate 
 
C08CA05 short-acting nifedipine Hypotension, constipation 
G03BA02 methyltestosterone Prostatic hypertrophy, cardiac problems 
G03C estrogens only (oral) Carcinogenic potential, lack of cardio protective effect  
H03AA05  desiccated thyroid Cardiac effects 
J01XE01 nitrofurantoin Renal impairment 
M01AB01indomethacin Central nervous system ADRs 
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Table 4. continued PIDs independent of diagnoses and conditions  
 
Potentially inappropriate drug Concern 
M01AB15 ketorolac Avoid because of elderly people’s asymptomatic 
pathological gastrointestinal conditions 
Non-selective longer half-life NSAIDs in  
long-term, full-dosage use:  
M01AE02 naproxen  
M01AE12 oxaprozin  
M01AC01 piroxicam 
Gastrointestinal bleeding, renal and heart failure, 
hypertension 





M03BX08 cyclobenzaprine  
G04BD04 short-acting oxybutynin 
Anticholinergic ADRs, effectiveness questionable 
N02AB02 meperidine (pethidine) Ineffective, causes confusion 
N02AC04 propoxyphene and comb. Few advantages over paracetamol, ADRs of other narcotic 
drugs 
N02AD01 pentazocine CNS ADRs 
N03AA barbiturates (except for 
seizures) 
Addictive, cause more ADRs than most sedative or 
hypnotic drugs 
N04AB02 orphenadrine Sedation and anticholinergic ADRs  
N05AC02 thioridazine  
N05AC03 mesoridazine 
Central nervous system and extrapyramidal ADRs 
N05BC01 meprobamate Highly addictive, sedation 
Long-acting benzodiazepines:  
N05BA02 chlordiazepoxide  
N05BA01 diazepam  
N05CD10 quazepam 
N05BA13 halazepam  
N05BA05 chlorazepate 
Sedation, risk for falls and fractures 
 
Short-acting benzodiazepines in high 
doses:  
N05BA06 lorazepam > 3 mg 
N05BA04 oxazepam > 60 mg  
N05BA12 alprazolam > 2 mg  
N05CD07 temazepam > 15 mg   
N05CD05 triazolam > 0.25 mg 
Smaller doses effective and safer 
N05CD01 flurazepam Extremely long half-life 





Table 4. continued PIDs independent of diagnoses and conditions 
 
Potentially inappropriate drug Concern 
 
N06AB03 fluoxetine daily CNS stimulation, sleep disturbances, increasing agitation 
N06BA01-03 amphetamines CNS stimulation ADRs 
Anticholinergics and antihistamines: 
R06AB02 chlorpheniramine 




R06AC04 tripelennamine  
R06AB02 dexchlorpheniramine  
Anticholinergic ADRs 
PIDs unavailable in Finland in 2003 are marked in italics.  
The code preceding the drug name refers to the ATC code.  
 
 
According to the Beers 2003 criteria, approximately 17% of all participants were 
PID users, ranging from 7% in Denmark to 25% in the Czech Republic. The PIDs most 
commonly used were pentoxifylline and diazepam. The most common PIDs 
(prevalence ≥3%) in Czech Republic were pentoxifylline, diazepam, and amiodarone; 
diaxepam and amitriptyline in Finland; unopposed estrogens in Iceland; amiodarone 
and ticlopidine in Italy; diazepam in the Netherlands and Norway; and amiodarone in 
the United Kingdom (Fialova et al. 2005). 
The use of PIDs is also common in nursing homes (Table 5). Factors associated 
with inappropriate prescribing among the elderly have included female gender, age, 
polypharmacy, poor physical functioning, no diagnosis of dementia, and several 
prescribers (Fick et al. 2008, Dhall et al. 2002, Dhalla et al. 2002). About one third of 
the nursing homes in Finland participate in benchmarking by using the Minimum Data 
Set (Noro et al. 2005, Morris et al. 1990), which also includes certain quality 
indicators for drug prescribing. 
2.4 Drug-drug interactions  
Drug interactions can be categorized into interactions between i) two or more 
drugs, ii) drug and disease or condition, iii) drug and food products, iv) drug and 
alcohol, and v) drug and natural products, such as herbs (Mallet et al. 2007). Figure 2 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Drug-drug interactions (adapted from Mallet et al. 2007) 
Aging, a high number of drugs, and several prescribers are risk factors for drug-
drug interactions (Mallet et al. 2007). In addition, older people are major users of 
complementary and alternative medicines, some of which are especially marketed to 
older people; consequently, the elderly are at high risk for herb-drug interactions 
(Hoblyn & Brooks 2005). 
High numbers of medications lead to high risk for adverse drug events. Drug 
interactions stemming from inhibition of metabolism increase the risk for adverse 
effects due to excess drug concentrations, whereas drug interactions resulting from 
induction of metabolism can lead to therapeutic failure due to inadequate drug 
exposure (Schwartz 2007). Few treatment guidelines based on randomized trials exist 
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for therapy in patients aged over 80 years, and guidelines developed for younger 
patients often recommend multiple drug regimens for treating disorders common 
among the older population: hypertension, diabetes, and coronary artery disease 
(Schwartz 2007). 
In a Norwegian nursing home study, which used the Norwegian Pharmaceutical 
Products compendium, 9% of 1042 residents were exposed to a potential DDI 
(Nygaard et al. 2003). The most probable consequences of these DDIs were impaired 
metabolism and excretion; only three patients used a drug combination that should 
always be avoided (Nygaard et al. 2003). Because nursing home residents are 
susceptible to DDIs due to their multiple diseases and polypharmacy, this 
phenomenon merits further research. 
2.5 Adverse drug events and reactions 
Any substance that is capable of producing a therapeutic effect can also produce 
unwanted or adverse effects (Edwards & Aronson 2000). An adverse drug event 
(ADE) is an injury resulting from the use of a drug and includes harm stemming from 
the drug itself or from use of the drug (Nebeker et al. 2004) (Figure 3). A side effect 
is a usually predictable or dose-dependent effect of a drug that is not the principal 
effect for which the drug was chosen; the side effect may be desirable, undesirable or 
inconsequential (Nebeker et al. 2004). An adverse drug reaction (ADR) is a subtype of 
side effects that represents an unintentional negative effect resulting from the drug 
used in normal doses (Nebeker et al. 2004). The World Health Organization has 
defined an ADR as “a response to a drug that is noxious and unintended and occurs at 
doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or 
for modification of physiological function” (WHO 1972). Others (Edwards & Aronson 
2000) have also suggested the definition “an appreciably harmful or unpleasant 
reaction resulting from an intervention related to the use of a medicinal product which 
predicts hazard from future administration and warrants prevention or specific 
treatment, or alteration of the dosage regimen or withdrawal of the product”. The 
terms adverse reaction and adverse effect are interchangeable, except that an 
adverse effect is identified from the point of view of the drug, and an adverse reaction 
is identified rom the point of view of the patient (Edwards & Aronson 2000). 
Pharmacovigilance is the study of drug-related injuries intended to provide 
warning or withdrawal recommendations for pharmaceutical products and is primarily 
concerned with adverse drug reactions and the properties of the drug in normal use 


















Figure 3. Drug-related harm (adapted from Edwards & Aronson 2000 and Nebeker et 
al. 2004) 
2.5.1 Adverse drug events and reactions in old age 
 
A disproportionately high number of serious adverse drug events occur in older 
people, even after adjusting for increased drug use (Moore et al. 2007). In a Dutch 
study of adverse drug reactions among the elderly in general practice, most adverse 
drug reactions stemmed from antibiotics, antihypertensive drugs, and NSAIDs 
(Veehof et al. 1999). In a meta-analysis of observational studies, adverse drug events 
accounted for nearly 5% of all hospitalizations in all age groups, and for 16.6% of 
hospitalizations among the oldest age group (Beijer & de Blaey 2002). In a US cross-
sectional survey of emergency department visits, adverse drug events accounted for 
2.5% of all emergency department visits and for 6.7% of hospitalizations (Budnitz et 
al. 2006). In individuals aged ≥ 65 years, ADEs accounted for 5.9% of emergency 
department visits and 8.8% of hospitalizations (Budnitz et al. 2006). The most 
common drugs implicated in ADEs were insulin, opioid-containing analgesics, 
anticoagulants, amoxicillin-containing agents, and antihistamines/cold remedies. 
These drugs accounted for 27.7% of estimated ADEs. The most common ADEs leading 
to hospitalization resulted from anticoagulants, insulin, opioid-containing analgesics, 
oral hypoglycaemic agents and antineoplastic agents; these ADEs accounted for 
38.4% of hospitalizations (Budnitz et al. 2006). A US cohort study that included 
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almost 29 000 nursing home resident-months identified 546 ADEs (1.89 per 100 
resident-months), of which 51% were considered preventable (Gurwitz et al. 2000).  
Factors responsible for increased ADEs in older people seem to be multiple drug 
use, including prescription and over-the-counter drugs, increased drug-drug 
interactions, pharmacokinetic and pharmacodynamic changes, drug therapy 
compliance, and aging itself (Beyth & Shorr 1999). Some of the hazards attributed to 
multiple drug use may actually be related to the comorbidities for which the drugs are 
prescribed (Hilmer et al. 2007b). 
In frail older people, ADEs may be numerous. ADEs may present as falls and 
confusion (Hilmer et al. 2007b). Among those elderly with multiple comorbidities and 
minimal functional reserve, and for whom evidence of the effectiveness of medication 
use to guide prescribing is limited, the impact that a change in medication regime has 
on physical function may be a clinically useful marker for drug response (Hilmer & 
Gnjidic 2009). The Kuopio 75+ study reported a significant difference between self-
reported ADRs (11.4%) and physician-observed ADRs (24%) (Lampela et al. 2007). 
The authors suggest that older people may ignore ADRs and consider them an 
unavoidable part of aging. Consequently, a physician should remain attentive to 
potential ADRs even though the elderly patient may not complain of drug-related 
problems (Lampela et al. 2007). The general wisdom in geriatric prescribing of 
initiating new drug regimens with low doses and slowly increasing the dosage is based 
on a concern for adverse drug reactions (McLean & Le Couteur 2004). 
2.5.2 Adverse drug reactions of psychotropic drugs 
Psychotropic drugs, along with anticoagulants, are the most common medications 
associated with preventable ADRs (Gurwitz et al. 2000). Older people may suffer from 
falls, as well as from anticholinergic and cognitive adverse drug reactions of these 
drugs (Leipzig et al. 1999, Cumming 1998). A systematic review consisting of 29 
studies identified psychotropics, including benzodiazepines, antidepressants, and 
antipsychotics, as the main group of drugs associated with falls in older people 
(Hartikainen et al. 2007). The Health, Aging and Body Composition Study of home-
dwelling older people associated the combined use of central nervous system drugs 
(benzodiazepines, opioid-reseptor agonists, antipsychotics, and antidepressants) with 
recurrent falls and cognitive decline (Hanlon et al. 2009, Wright et al. 2009). A recent 
review of psychotropic drugs and falls consisting of 17 studies found strong evidence 
that the use of multiple drugs, antidepressants, and anti-anxiety drugs is associated 
with higher risk for falls (Sterke et al. 2008). The evidence for the association of other 
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psychoactive drugs with risk for falls was limited or inconclusive. The Kuopio 75+ 
study compared the risk of mortality in home-dwelling elderly with a diagnosis of 
dementia. Compared to non-users of psychotropics, the hazard ratio for mortality 
among individuals with antipsychotics as their only psychotropic medication was 2.75, 
and among concomitant users of all kinds of psychotropics, 1.76 (Hartikainen et al. 
2005). 
Selective serotonin reuptake inhibitors (SSRIs) can cause hyponatremia and 
serotonergic syndrome, as well as bleeding when combined with non-steroidal anti-
inflammatory drugs (NSAIDs). Tricyclic antidepressants can lengthen QT time and 
cause cardiac dysrhythmias (van Noord et al. 2009, Pelkonen & Ruskoaho 2003). 
Atypical antipsychotic drugs have been associated with several ADRs, including 
cerebrovascular events (Wooltorton 2002b, Wooltorton 2004), cardiac events 
(Wooltorton 2002a), hyperglycemia, and diabetes (Wooltorton 2004), and higher 
mortality (Singh & Wooltorton 2005). In a Canadian nursing home study, facilities 
with more intense antipsychotic drug use presented higher mortality rates despite 
more favourable clinical characteristics at resident admission (Bronskill et al. 2009). 
The risk of death is highest after 30 days of initiation of an atypical antipsychotic (OR 
3.2, 95% CI, 2.8 to 3.7) (Rochon et al. 2008). The risk of death is even higher among 
users of conventional antipsychotics (Wang et al. 2005). In a Finnish survey of 49 
medico legal autopsies, sudden unexpected death was especially associated with 
thioridazine (Mehtonen et al. 1991). A meta-analysis of 15 trials of atypical 
antipsychotics reported the following ADRs: somnolence, urinary tract infection, 
extrapyramidal effects, abnormal gait, edema, cerebrovascular adverse events 
(Schneider et al. 2006), and elevated risk of mortality (Schneider et al. 2005). In a 
Finnish follow-up study, however, conventional and atypical antipsychotics failed to 
raise the risk of mortality or hospital admissions among nursing home and geriatric 
ward patients with dementia, and in multivariate analysis, atypical antipsychotics 
seemed to decrease the risk of mortality (Raivio et al. 2007). 
Whether an unwanted symptom is an ADR or results from the underlying disease 
or condition for which the drug was prescribed is not self-evident. For example, a US 
study consisting of over 34 000 nursing home residents found an association between 
falls and insomnia; surprisingly, hypnotic use failed to predict falls (Avidan et al. 
2005). Another US study compared hip fracture rates in the states of New York and 
New Jersey after the state of New York implemented a regulatory action on 
prescribing benzodiazepine. The regulatory action resulted in a 60% reduction in 
benzodiazepine use in New York. Even so, the incidence of hip fractures remained 
unchanged (Wagner et al. 2007). 
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Appropriate psychotropic prescribing may reduce the incidence of ADRs. Atypical 
antipsychotics, for example, enjoy advantages over conventional antipsychotics, 
including fewer extrapyramidal ADRs (Jeste et al. 1999), and short-acting 
benzodiazepines are preferable to long-acting benzodiazepines (Fick et al. 2003). 
Because tricyclic antidepressants can cause anticholinergic ADRs, and long half-life 
fluoxetine can induce excessive CNS stimulation, avoiding such drugs has been 
recommended (Fick et al. 2003, Leipzig et al. 1999). 
2.5.3 Adverse drug reactions of potentially inappropriate drugs 
In a French study that comprised over 2000 older patients admitted to an acute 
geriatric unit and used modified Beers 1997 criteria of potentially inappropriate drugs 
found that 66% of patients received PIDs on hospital admission (Laroche et al. 
2007b). The most common PIDs were anticholinergic antidepressants, cerebral 
vasodilators, and long-acting benzodiazepines. The prevalence of ADRs was 20% 
among patients receiving PIDs, and 16% among patients receiving no PIDs. After 
adjusting to confounding factors, however, no PIDs were associated with increased 
risk for ADRs. The main preventable factor in ADRs seems to be reducing the number 
of drugs (Laroche et al. 2007b). 
An Italian study of 500 recently hospitalized elderly patients investigated the 
relationship between PIDs independent of diagnoses according to the Beers 2003 
criteria and the Loss of Activities of Daily Living (Corsonello et al. 2009). At hospital 
admission, 21% of patients were taking at least one PID, and 10% of patients 
received new prescriptions of at least one PID during their hospital stay. The most 
prevalent PIDs at baseline were ticlodipine, doxazosin, and amiodarone. The most 
frequently prescribed new PIDs were ticlodipine, long-acting benzodiazepines, and 
ferrous sulphate > 325 mg/day. Functional decline was unassociated with PID use, 
but was strongly associated with ADRs to any drugs (Corsonello et al. 2009). 
A US survey investigated inappropriate medication as a risk factor for one-year 
self-reported ADRs (Chrischilles et al. 2009). The study cohort comprised over 600 
elderly people with a mobility disability, and the criteria for inappropriate medication 
use were PIDs independent of and dependent on diseases and conditions according to 
the Beers 1997 criteria, DDIs and therapeutic duplication. Of all the participants, 51% 
were exposed to inappropriate medication use, 32% used PIDs independent of 
diseases or conditions, 30% were experienced a drug-disease interaction, and 6% 
were exposed to therapeutic duplication. The most frequent PIDs included 
propoxyphene, amitriptyline, and oxybutynine. The one-year self-reported prevalence 
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of ADR was 30% among participants using PIDs, and 14% among those using only 
appropriate medications. In multivariate analysis, all measures of inappropriate 
medication use were significantly associated with self-reported ADRs (Chrischilles et 
al. 2009). 
In a US study with a sample of nearly 17 000 community-dwelling elderly, the use 
of PIDs according to the Beers 2003 criteria raised the risk for health care utilization 
1.5-2 times higher than did the non-use of PIDs (Fick et al. 2008).    
In another US survey investigating older adults’ visits to the emergency 
department due to ADEs, nearly 4% of emergency department visits involved PIDs 
(according to the Beers 2003 criteria) (Budnitz et al. 2007). Warfarin, insulin, and 
digoxin accounted for 33% of the ADEs leading to emergency department visits. 
Accounting for the frequency of outpatient prescription, the risk for emergency 
department visits due to warfarin, insulin, and digoxin was 35 times greater than for 
PIDs (Budnitz et al. 2007). Adverse healthcare outcomes of PIDs appear in Table 6.  
 
 
Table 6. Adverse healthcare outcomes of PIDs in nursing homes according to the 
Beers criteria (modified from Jano & Aparasu 2007) 
 
Authors N Design Mortality Hospitalization Other outcome 
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Lau et al. 
2005 
3 372 retrospective 
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(95% CI, 1.05-
1.55)  
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2.6 Tools for improving the quality of prescribing 
Tools for assessing the appropriateness of older people’s drug therapies have been 
developed to prevent drug therapy-related adverse events in older patients (Fick et 
al. 2003, Beers et al. 1991, Beers 1997, McLeod et al. 1997, Naugler et al. 2000). 
Measures for assessing prescribing may be criterion-based and explicit or judgement-
based and implicit (Spinewine et al. 2007). Criteria used with prescription data alone 
or combined with clinical data may include lists of “drugs to avoid” or drugs that may 
interact with each other. Criteria for detecting underprescribing may indicate an 
evidence-based need for using a certain drug for a specific condition if no 
contraindication exists (Barry et al. 2007). Misprescribing criteria focus on drug 
choice, dose, drug interactions, duration of drug therapy, duplication,  and follow-up 
(Spinewine et al. 2007).  
The explicit criteria are drug- or disease-oriented, relatively easy to use, and may 
define the minimum level of quality of prescribing (Spinewine et al. 2007). Explicit 
criteria include the Beers criteria for older adults (Fick et al. 2003, Beers et al. 1991, 
Beers 1997) as well as the McLeod (McLeod et al. 1997) and Zhan (Zhan et al. 2001) 
criteria, the Improving Prescribing in the Elderly Tool (IPET) (Naugler et al. 2000), 
Assessing Care of the Vulnerable Elder (ACOVE) (Shekelle et al. 2001a and 2001b), 
Screening Tools to Alert Doctors to the Right Treatment (START) (Barry et al. 2007), 
the Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions (STOPP) 
(Gallagher & O’Mahony 2008), and the French consensus panel list of potentially 
inappropriate medications in the elderly (Laroche et al. 2007a). At the moment, 
Finnish experts in geriatric drug therapy are preparing a database to support 
appropriate prescribing to older adults in Finland (Mäntyranta T., oral communication 
10.3.2010). 
Some of the above-mentioned tools were developed using the Delphi consensus 
method (Fick et al. 2003, Beers et al. 1991, Beers 1997, Barry et al. 2007, Gallagher 
& O’Mahony 2008, Laroche et al. 2007a). With this method, a panel of experts is 
presented with statements. The experts then individually rate their level of agreement 
with the statements and may supplement them or suggest other statements. This 
procedure is repeated until the experts reach consensus. Even though the experts in 
the Delphi process may use evidence-based medicine in formulating the statements, 
the tool must nevertheless be validated.  
Explicit drug-drug interaction criteria are often embedded in computerized 
programs such as Medi-span (www.medispan.com), Lexi-Comp (www.lexi.com), 
CPOE-CDS (Rochon et al. 2006), or Swedish, Finnish, INteraction X-referencing, 
SFINX (Lääkeinteraktiot SFINX). Introduced in 2006, SFINX is a commercial medical 
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drug-drug interaction database that is updated quarterly by specialists in clinical 
pharmacology at the Turku University Hospital, the Karolinska Institutet, and the 
Stockholm county council (Lääkeinteraktiot SFINX). A Swedish interaction database 
(www.fass.se), which preceded SFINX, is now embedded in it. In October 2009, the 
SFINX database contained more than 9000 DDIs. The clinical significance of the 
interactions is classified from A to D. Significance level A means the interaction is 
clinically insignificant, and significance level D means the interaction is clinically 
significant and that the combination should be avoided.  
A medication exposure measure associated with functional outcomes may also be 
a useful prescribing tool (Hilmer & Gnjidic 2009). The Drug burden index is an 
integrated model of exposure to medications most consistently associated with 
functional impairment (e.g. medications with anticholinergic and sedative effects) 
(Hilmer et al. 2007a). The Drug burden index is a linear additive model that 
incorporates pharmacokinetics (dose) and pharmacodynamics (dose response, 
maximal effect) to measure cumulative exposure to anticholinergic and sedative 
medications. The Drug burden index has been independently associated with the 
impairment of physical performance and cognition (Hilmer et al. 2007a).  
Implicit criteria include clinical assessment of the appropriateness of drug therapy 
and focus on the patient rather than on drugs or diseases (Spinewine et al. 2007, 
Roth et al. 2009). Compared to explicit criteria, implicit criteria are more 
comprehensive, but also more complicated to use (Spinewine et al. 2007). 
The Medication Appropriateness Index (MAI) classifies patient’s every medication 
as appropriate, marginally appropriate, or inappropriate based on ten criteria: 
indication, effectiveness, dosage, directions, practicality, drug-drug interactions, 
drug-disease interactions, unnecessary duplication, duration, and cost (Spinewine et 
al. 2006, Samsa et al. 1994). This index produces a summated score to provide an 
overall measure of the appropriateness of medication use. However, the index fails to 
take into account underprescribing, drug allergy, adverse drug reactions, and 
compliance, and is tedious to use (Spinewine et al. 2006, Samsa et al. 1994). 
According to the authors, the index has excellent reliability and validity as well as 
good interrater and intrarater agreement (Samsa et al. 1994). However, the index 
has shown lower reliability in assessments by other researchers, and some have 
offered recommendations for improving the instrument’s reliability and validity 
(Spinewine et al. 2006). Nevertheless, the MAI is a comprehensive, if time-consuming 
(Stuijt et al. 2008), measure for assessing the appropriateness of an individual 
patient’s drug therapy. 
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Tools for improving the quality of prescribing have some inconveniences. Explicit 
criteria have low specificity, and consequently, a drug labeled inappropriate for older 
adults may in some cases be appropriate or otherwise harmless. In addition, these 
criteria fail to take into account an individual patient’s characteristics, comorbidities, 
or adherence. Moreover, the real problem in prescribing for the elderly may actually 
be underprescribing (Spinewine et al. 2007). Implicit criteria are complicated and 
time consuming, and their reliability may depend on the expertise of the applier 
(Spinewine et al. 2007, Roth et al. 2009). 
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3 The aims of the study  
This study explores dimensions of appropriate prescribing among elderly nursing 
home residents in Helsinki. The specific aims were: 
 
1. To describe the use of psychotropic drugs and associated factors among 
residents with and without dementia (I); 
 
2. To assess the prevalence of laxatives and to identify factors and medications 
associated with the regular use of laxatives (II); 
 
3. To clarify the use of vitamin D and calcium and the associations between 
vitamin D and calcium supplementation and nutritional status, diseases, and daily 
routines of nutritional care (III);  
 
4. To describe the prevalence of potentially inappropriate drugs according to the 
Beers 2003 criteria, and potential class D drug-drug interactions according to the 
SFINX database (“clinically significant interaction, and the combination should be 
avoided”) (IV); 
 
5. To describe differences in drug prescribing in public and private nursing homes. 
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4 Subjects and methods 
4.1 Study populations 
The cross-sectional material for this study was collected during February 2003 
from all nursing homes in Helsinki, Finland as part of a larger project investigating the 
nutritional status of nursing home residents (Muurinen et al. 2003). The inclusion 
criteria for Studies I, II, and IV were long-term residency, the availability of sufficient 
information about demographic factors and medication, willingness to participate, and 
age ≥ 65 years. The inclusion criteria for Study III were long-term residency, 
sufficient information on the use of vitamin D and calcium supplements, and 
willingness to participate.  
In February 2003, 1088 persons were residing in 4 public nursing homes, and 
1336 in 16 private nursing homes. Of the 2424 total residents, 132 (5.4%) were in 
respite care for one to two weeks, 150 (6.2%) were in short-term rehabilitation, and 
22 (0.9%) refused to participate. Of the residents assessed, 2025 possessed sufficient 
medical and demographic data for Studies I, II, and IV. Residents aged < 65 years 
(n=38) were excluded, leaving 1987 residents (82%) who were eligible for further 
analysis. For Study III, 2114 long-term residents were willing to participate and had 
sufficient information on the use of vitamin D and calcium supplements (Figure 4). 
4.2 Methods 
4.2.1 Background data  
The study questionnaire (Appendix 1) consisted of the Mini Nutritional Assessment 
and a questionnaire about the resident’s background information and health status, 
including his or her medication records.  
Nurses trained to use the MNA and to complete the study questionnaire were 
assigned to each home ward. These nurses organized the data collection, assessed 
the residents’ health status and retrieved data on demographic factors, regularly 
administered medications, and diagnoses from the residents’ medical records.  
Residents whose medical records indicated a diagnosis of dementia or who were 
using either anticholinesterase or memantine were classified as having a diagnosis of 
dementia. The criterion for depression was a Resident Assessment Instrument (RAI) 
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Figure 4. Flow chart of the study populations 
depression score of ≥ 3 (range 0 to 14) (Burrows et al. 2000). The Charlson 
comorbidity index served to assess multimorbidity (Charlson et al. 1987). Residents’ 
mobility was dichotomized into unable to move independently (bed-ridden residents 
and residents using a wheelchair) and others.  
Each resident was assessed using the Mini Nutritional Assessment (MNA). The 
overall MNA score distinguishes elderly patients: i) with good nutritional status (MNA 
score 24-30 points), ii) at risk for malnutrition (MNA score 17-23.5), and iii) who are 
malnutrished (MNA score < 17) (Vellas et al. 1999). 
Whether a resident received snacks between meals was inquired with a yes/no 
question. Snacks in Finland usually mean yogurt, dark bread, or fruits. How much of 
the main meal the resident eats on average was inquired with answer options “less 
than half, half, nearly all or all”. This response was dichotomized to “eating less than 
half or half” and to “nearly all or all”. The nurses were instructed to make their 
estimations of the amount of food eaten as well as of other factors related to 
nutritional care over the preceding three months. 
All data were collected and analyzed anonymously. Patients and proxies were 
informed about the study and their consent was an inclusion criterion. The City of 
Helsinki ethics committee granted permission for the study. 
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4.2.2 Medication use  
The medication data were collected as point prevalence in February 2003. Nursing 
home personnel either handwrote the medication record onto the resident’s study 
questionnaire or printed the medication record as an appendix. 
A resident was classified as a drug user if his or her medication record indicated a 
regular sequence of drug administration. Others, including those whose medication 
records indicated permission for the nurse to administer the drug, if necessary, on an 
as-needed basis, were classified as non-users. The drugs were coded according to 
their Anatomical Therapeutic Chemical (ATC) classification index (ATC DDD 2009). 
Nine or more drugs daily was the cut-point for polypharmacy (Hanlon et al. 2001). 
4.2.3 Psychotropic medication 
This study investigated the use of the following psychotropic drugs: antipsychotics 
N05A, antidepressants N06A, anxiolytics N05B, hypnotics N05C, and antidementia 
drugs N06D (ATC DDD 2009).  
Antipsychotics were divided into conventional (chlorpromazine, chlorprothixene, 
flupentixol, fluphenazine, haloperidol, levomepromazine, melperone, pericyazine, 
perphenazine, promazine, sulpiride, thioridazine, zuclopenthixol) and atypical 
antipsychotics (clozapine, olanzapine, quetiapine, risperidone).  
Antidepressants were classified as selective serotonin re-uptake inhibitors 
(citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), tricyclic antidepressants 
(amitriptyline, clomipramine, doxepin, nortriptyline, trimipramine), and other 
antidepressants. 
Long-acting benzodiazepines (diazepam, chlordiazepoxide) (Fick et al. 2003) were 
separated from other benzodiazepine anxiolytics (alprazolam, lorazepam, oxazepam) 
and from anxiolytics other than benzodiazepines (buspirone, clomethiazole).  
All hypnotics (midazolam, nitrazepam, temazepam, zopiclone, zolpidem) were 
coded into a single group.  
The antidementia drugs used were divided into anticholinesterases (donepezil, 
galantamine, rivastigmine) and memantine. 
Mean and median doses for the most frequently used preparations of conventional 
and atypical antipsychotics, antidepressants, anxiolytics, and hypnotics were 
compared with the Defined Daily Dose (DDD), the assumed average daily 
maintenance dose for a drug used for its main indication in an adult (ATC DDD 2009). 
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4.2.4 Laxatives 
The following laxatives were available in Finland at the time of data collection: 
senna, bisacodyl, and sodium picosulfate (stimulant laxatives A06AB); seeds of 
plantago ovata (bulk laxatives A06AC); and saline laxatives, macrogol, lactulose, and 
lactitol (osmotic agents A06AD). In addition, the following medications were classified 
as laxatives, per the suggestions of prior studies (DiPalma 2004), although they are 
used mainly for other indications: metoclopramide, cisapride, and cholinergic agents 
carbamylcholine, pyridostigmine, and distigmine (neuromuscular agents). 
Drugs which, according to the medical literature (van Dijk et al. 1998, Harari et al. 
1995, Monane et al. 1993, Dosh 2002), may cause constipation were classified as 
potentially constipation-inducing drugs. In addition, drugs which, according to the 
product summaries in Pharmaca Fennica 2006, may induce constipation were taken 
into analyses; we also included into our analyses other drugs of that same class. 
The drugs classified as potentially constipation-inducing are as follows: 
acetazolamide, antiepileptics, baclofen, α1-adrenoceptor antagonists, histamine H2-
receptor antagonists, proton pump inhibitors, antacids, bisphosphonates, β-
adrenoceptor antagonists, diuretics, HMG-CoA reductase inhibitors (statins), lipid-
lowering drugs other than statins, ACE inhibitors, verapamile and nifedipine, calcium 
channel antagonists other than verapamil and nifedipine, opioids, paracetamol, 
acetylsalicylic acid, cyclo-oxygenase-2 selective NSAIDs, nonselective NSAIDs, 
antiparkinsonian drugs, anticholinergic drugs for urinary incontinence, calcium 
supplements, iron supplements, atypical antipsychotics, conventional antipsychotics, 
all antidepressants, tricyclic antidepressants, SSRIs, antidepressants other than 
tricyclics, and SSRIs and anxiolytics.  
4.2.5 Vitamin D and calcium supplements 
The use of vitamin D and calcium supplementations were inquired with yes/no-
questions such as “Does the resident receive a vitamin D supplement?” or “Does the 
resident receive a calcium supplement?” Those answering “yes” or whose medical 
record indicated that they receive calcium or vitamin D supplements were considered 
supplement users. Because the use of vitamin D and calcium supplements was also 
inquired with a specific question in the questionnaire about the resident’s background 
information and health status, an incomplete medication record was not an exclusion 
criterion for Study III, and consequently, the study population (N=2114) was larger 
than in Studies I, II, and IV (N=1987). 
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4.2.6 Potentially inappropriate medications 
The Beers criteria 2003 identify PID use among older adults both independent of 
diagnoses or conditions as well as taking them into account (Fick et al. 2003). This 
study used the criteria independent of diagnoses or conditions. The following drugs 
included in the criteria were unavailable in Finland in 2003: pentazocine, 
trimethobenzamide, methocarbamol, metaxalone, cyclobenzaprine, flurazepam, 
quazepam, halazepam, chlorazepate, methyldopa, reserpine, chlorpropamide, 
dicyclomine, propantheline, chlorpheniramine, cyproheptadine, promethazine, 
dexchlorpheniramine, meperidine, ticlodipine, oxaprozin, cascara sagrada, Neoloid 
(castor oil), guanethidine, guanadrel, doxazosin, mesoridazine, mineral oil, 
cimetidine, ethacrynic acid, desiccated thyroid, and amphetamines. 
4.2.7 Drug-drug interactions 
Swedish, Finnish, INteraction X-referencing SFINX is a commercial medical drug-
drug interaction (DDI) database. Introduced in 2006, SFINX is updated quarterly by 
specialists in clinical pharmacology at the Turku University Hospital, Finland as well as 
at the Karolinska Institutet and Stockholm county council, Sweden (Lääkeinteraktiot 
SFINX). The interactions in the SFINX database are classified according to their 
clinical significance and level of documentation. Clinical significance is classified from 
A to D; A means the interaction is clinically insignificant, whereas D means the 
interaction is clinically significant and the combination should be avoided. This study 
investigates the prevalence of potential class D DDIs in the nursing home population.  
4.2.8 Statistical methodology 
The research secretary entered the data into Microsoft Excel 2002. Residents’ 
medication lists were checked, and input errors were corrected one by one. The coded 
data were analyzed using the Statistical Package for the Social Sciences (SPSS) 
versions 12.0.1 and 15.0, and NCSS statistical analysis and graphics software. 
Drug users were compared to non-users with the X2-test or with Fischer’s exact 
test, when appropriate. The independent sample T-test served to compare mean ages 
and numbers of daily drugs. P-values of < 0.05 were considered statistically 
significant. Confidence intervals were calculated with Confidence Interval Analysis 
version 1.0 (Gardner & Altman 1989).  
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Multivariate analyses were performed with NCSS using logistic regression analysis. 
In the study on the use of laxatives, multivariate logistic regression analysis served to 
determine which statistically significant variables in the univariate analyses were 
independently associated with the use of laxatives. Age > 80 years, previous stroke, 
Parkinson’s disease, inability to move independently, poor Mini Nutritional Assessment 
score (< 17), a fluid intake of less than five glasses daily, chewing problems, a high 
number of drugs other than laxatives and constipation-inducing drugs, and snacks 
between meals served as covariates in multivariate analysis. In the vitamin D and 
calcium study, age > 80 years, gender, poor Mini Nutritional Assessment score (< 
17), a poor Activities of Daily Living score (ADL) (≥ 4), lactose intolerance, 
constipation according to the MNA questionnaire, previous hip fracture, eating half or 
less of meal proportions offered, snacks between meals, and weight monitoring no 
more than once annually served as covariates. 
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5 Results 
5.1 Baseline data 
Of the 1987 elderly residents assessed in Studies I, II, and IV, 80.7% were 
female. The residents’ mean age was 83.7 (SD 7.7). The percentage of widowed 
residents was 53%, and 53.5% had received no more than a primary school 
education. The proportion of residents with a diagnosis of dementia was 69.5%. The 
mean number of drugs consumed daily was 7.9 (SD 3.6). The mean number of drugs 
in residents with a diagnosis of dementia was 7.4 (SD 3.3), and in residents with no 
diagnosis of dementia, 9.06 (SD 3.9). Females consumed a higher number of daily 
drugs than did men: 8.03 (SD 3.6) and 7.4 (SD 3.5), respectively. In Study III 
(n=2114), the mean age was 83 years, and 80.7% were female. 
Residents in private nursing homes (N=914) were older, more often female, 
widowed, with a diagnosis of dementia, better nourished, and with a higher Charlson 
comorbidity index than were residents in public nursing homes (N=1073). Residents 
in public nursing homes more often had stroke and poor mobility than did residents in 
private nursing homes (Table 7).  
5.2 Psychotropic medication 
Altogether 79.7% of all residents were prescribed psychotropic drugs (Table 8).  
Antipsychotic drugs were administered to 42.6% of residents, and 5.3% of all 
residents received ≥ 2 antipsychotic drugs. Altogether 18.9% of the residents 
received conventional antipsychotics, and 27.0% received atypical antipsychotics. The 
prevalence of antipsychotics was higher among younger residents: 51.8%, 42.1%, 
and 31.3% among residents aged 65 to 79 years, 80 to 90 years, and > 90 years, 
respectively. 
Of all residents, 44.6% received antidepressants, and the percentage of residents 
receiving more than one antidepressant was 2.7%. SSRIs were the most common 
antidepressants, used by 27.6% of residents. Fluoxetine, an antidepressant 
considered inappropriate for the elderly because of overstimulation of the central 
nervous system, sleep disturbances, and agitation (Fick et al. 2003), was 
administered to 1.3% of residents, and 3.1% received tricyclic antidepressants. Of all 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 8. The use of psychotropic drugs in nursing homes in Helsinki 
* Χ 2-test, residents with dementia compared with residents without dementia or females compared with males. 
Statistically significant p-values (≤ 0.05) marked with bold letters. BZD=benzodiazepine. NA=not applicable.  
 
 
received mirtazapine. Of those residents diagnosed with depression (RAI depression 
score ≥ 3), 47.3% used antidepressants.  
One or more anxiolytic drugs were regularly administered to 26.3% of residents, 
and 27.5% used hypnotics. 
Of those residents diagnosed with dementia, 10.4% used cholinesterase inhibitors 
and 0.2% used memantine. Two residents received both memantine and 
cholinesterase inhibitor (Table 8). 
Men used any antipsychotics and conventional antipsychotics significantly more 
often than did women; the use of anxiolytics other than benzodiazepines was also 
more common among men. Women used SSRIs more often than did men (Table 8). 
The dosages of various psychotropic drugs were moderate. Haloperidol, used by 
4.7% of residents, had a mean dose of 1.5 mg (18.8% of DDD), and the median dose 
was 1 mg (range 0.5-9 mg). Risperidone, used by 16.6% of residents, had a mean 
dose of 0.9 mg (15% of DDD), and the median dose was 0.75 mg (range 0.25-7 mg). 



















Psychotropic drug 79.7 77.6 84.5 <0.001 80.0 78.6 0.56 
Antipsychotic drug 42.6 43.3 41.0 0.34 41.5 47.1 0.05 
Conventional 18.9 17.8 21.3 0.07 17.8 23.2 0.02 
Atypical 27.0 28.3 24.2 0.06 26.8 27.9 0.68 
Antidepressant 44.6 41.4 51.9 <0.001 46.4 37.2 0.001 

















Anxiolytic drug 26.3 25.3 28.5 0.13 26.1 27.3 0.61 
Long-acting BZD 
Other BZD 






















Hypnotics 27.5 22.8 38.1 <0.001 26.8 30.5 0.14 
Anticholinesterases 7.2 10.4 NA NA 7.4 6.5 0.56 
Memantine 0.2 0.3 NA NA 0.2 0.0 0.33 
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DDD), and the median dose was 20 mg (range 10-40 mg). Oxazepam was received 
by 14.0% of residents; its mean dose was 17.3 mg (34.6% of DDD), and its median 
dose was 15 mg (range 3.75-60 mg). Of all residents, 17.7% received temazepam; 
the mean dose was 19.1 mg (95.5% of DDD), and the median dose was 20 mg 
(range 10-40 mg). 
5.3 Laxatives 
Of all residents, 55.3% (n=1099) received laxatives regularly. Most of the laxative 
users received osmotic agents (45.8%). The use of stimulant laxatives (14.3% of all 
residents) was also common. Bulk laxatives were used by 4.0% of residents, and 
neuromuscular agents by 1.4%. In addition, 0.9% of residents were using 
unidentified laxatives. Of all residents, 11.5% used ≥ 2 different laxatives 
simultaneously (see Paper II: Results).  
The factors associated with regular laxative use in univariate analyses were 
advanced age, previous stroke, Parkinson’s disease, inability to move independently, 
malnutrition (MNA score < 17), a fluid intake of less than five glasses daily, and 
chewing problems. Residents eating snacks between meals used laxatives less often 
than did those eating no snacks: 42.3% and 51.0%, respectively. 
The potentially constipation-inducing drugs associated with regular laxative use 
were opioids, antacids, diuretics, tricyclic antidepressants, cholesterol-lowering drugs 
other than statins, histamine-2 blockers, non-selective NSAIDs, anticholinergic drugs 
for urine incontinence, and calcium channel blockers other than verapamil and 
nifedipine. Of all residents, 58.2% used one or more of these constipation-inducing 
drugs found in the univariate analysis; 63.0% of laxative users and 52.3% of laxative 
non-users received one or more constipation-inducing drugs (p-value < 0.001). The 
mean number of daily drugs, excluding laxatives and drugs associated with laxative 
use, was 6.6 (SD 3.1) for laxative users and 6.2 (SD 3.1) for non-users (p=0.001). 
We performed a multivariate logistic regression analysis in which age over 80 
years, gender, previous stroke, Parkinson’s disease, inability to move independently, 
a poor MNA score (< 17), a fluid intake of less than five glasses daily, chewing 
problems, eating snacks between meals, and a high number (> 7) of drugs other than 
laxatives or constipation-inducing drugs found in the univariate analysis served as 
covariates. In this analysis, age over 80 years (OR 1.29 [95% CI, 1.03 to 1.60]), the 
inability to move independently (OR 1.80 [95% CI, 1.42 to 2.28]), a poor MNA score 
(< 17) (OR 1.51 [95% CI, 1.19 to 1.93]), chewing problems (OR 1.27 [CI, 95% 1.00 
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to 1.61]), Parkinson’s disease (OR 1.63 [95% CI, 1.01 to 2.64]), and a high number 
(> 7) of drugs other than laxatives and constipation-inducing drugs found in the 
univariate analysis (OR 1.06 [95% CI, 1.03 to 1.09]) were associated with the use of 
laxatives. Eating snacks between meals (OR 0.74 [95% CI, 0.60 to 0.90]) was 
associated with lower risk for laxative use. 
5.4 Vitamin D and calcium supplements 
Nearly one third (32.9%) of all nursing home residents (n=2114) received vitamin 
D supplementation, and 29.2% were administered calcium supplements. Altogether 
20.0% of residents received both vitamin D and calcium supplementation.  
Factors associated with more frequent vitamin D supplementation were female 
gender (p=0.01), lactose intolerance (p < 0.001), better nutritional status (p=0.005), 
a higher Activities of Daily Living (ADL) score (p=0.004), eating snacks between 
meals (p < 0.001), and regular weight monitoring (p < 0.001). Residents with 
constipation, according to the MNA questionnaire, received vitamin D supplementation 
less often than did those without constipation (p=0.008).  
Residents receiving calcium supplementation had constipation less often than did 
residents receiving no calcium supplements: 40.6% vs. 46.6%, p=0.01). Of those 
residents with lactose intolerance, 44.4% received calcium supplementation 
compared to 27.6% who were lactose tolerant p<0.001). 
The dosage of vitamin D varied between 3 µg and 40 µg (120-1600 IU).  Of all 
residents, 21.2% received vitamin D in doses of ≥ 10 µg (400 IU), the 
recommendation at the time of the data collection (Ministry of Social Affairs and 
Health 2003). Only 3.5% of residents received vitamin D in excess of 20 µg (800 IU), 
an effective dose for preventing fractures. 
In logistic regression analysis where age, gender, malnutrition (MNA score < 17), 
poor physical functioning (Activities of Daily Living score ≥ 4), lactose intolerance, 
constipation, previous hip fracture, eating half or less of the food portion offered, and 
weight monitoring no more than once annually served as covariates, eating snacks 
predicted the use of vitamin D supplementation in doses of ≥ 10 µg (400 IU) (OR 
1.65, 95% CI, 1.25-2.17). Weight monitoring no more than once annually (OR 0.47, 
95% CI, 0.27-0.81) and malnutrition (MNA score < 17) (OR 0.57, 95% CI, 0.42-0.79) 
were risk factors for the inadequate use of vitamin D supplements. In this analysis, 
gender, age, lactose intolerance, poor physical functioning, constipation, and previous 
hip fracture proved insignificant. 
 57
5.5 Inappropriate prescribing 
5.5.1 Polypharmacy 
Altogether 40.3 of the nursing home residents consumed ≥ 9 drugs daily, a cut-off 
point  for polypharmacy among nursing home residents (Hanlon et al. 2001). No 
significant difference in exposure to polypharmacy existed between females and 
males. Residents consuming ≥ 9 drugs daily more often had previous stroke (p < 
0.001, 95% CI, -0.125 to -0.04), current depression (p = 0.001, 95% CI, -0.138 to -
0.035) or received psychotropic medication (p < 0.001, 95% CI, -0.233 to -0.168) 
than did those consuming < 9 drugs daily. Residents consuming ≥ 9 drugs daily were 
diagnosed with dementia (p < 0.001, 95% CI, 0.111-0.193) or poor nutritional status 
(MNA score < 17) (p < 0.01, 95% CI, 0.013-0.093) less often than residents who 
received < 9 drugs daily. 
5.5.2 Potentially inappropriate drugs 
Of all nursing home residents, 34.4% used PIDs according to the Beers 2003 criteria 
of potentially inappropriate medication use among older adults independent of 
diagnoses or conditions (Fick et al. 2003). Of all residents, 5.3% (n=105) used two 
PIDs, 0.7% (n=14) used three PIDs, two residents used four PIDs, and one resident 
used five PIDs simultaneously. Factors associated with PIDs were polypharmacy (≥ 9 
drugs daily), psychotropic drug use, and no diagnosis of dementia. Users and non-
users of PIDs showed no difference in age, gender, level of education, widowhood, 
previous stroke, depression, ability to move independently, or malnutrition (see Paper 
IV: Results).  
The most prevalent PIDs in our study population were short-acting 
benzodiazepines in greater-than-recommended doses (13.9% of all residents), 
hydroxyzine (7.1%), nitrofurantoin (6.3%), long-acting benzodiazepines (2.4%), and 
amitriptyline and its combinations (2.2%). Temazepam > 15mg, used by 13.5% of all 
residents, accounted for most of the short-acting benzodiazepine use in greater-than-
recommended doses. The mean dose of temazepam was 19.1 mg, and the median 
dose was 20 mg (range 10-40 mg). The three most frequently used PIDs – 
temazepam (> 15 mg), hydroxyzine, and nitrofurantoin – accounted for 76.9% of all 




Table 9. PIDs in nursing homes in Helsinki 
Potentially inappropriate drug Residents using the drug, % (n) 




A06AB02 bisacodyl (without opiate) 0.8 (16) 
B01AC07 short-acting dipyridamole  0.75 (15) 
B03AA07 ferrous sulphate > 325 mg/day 0.45 (9) 
C01AA05 digoxin > 0.125 mg/day (except when 
treating atrial arrhythmias) 
0.7 (14) 
C01BA03 disopyramide 0.05 (1) 
C01BD01 amiodarone 0.15 (3) 
C04AE01 ergot mesyloids  0.5 (10) 
G03C estrogens only (oral) 1.15 (23) 
J01XE01 nitrofurantoin 6.3 (125) 
Non-selective longer half-life NSAIDs in  
long-term, full-dosage use:  
M01AE02 naproxen  
M01AC01 piroxicam 
0.45 (9) 
G04BD04 short-acting oxybutynin 1.1 (22) 
N02AC04 propoxyphene and comb. 0.3 (6) 
N04AB02 orphenadrine 0.35 (7) 
N05AC02 thioridazine 0.6 (12) 
N05BC01 meprobamate 0.4 (8) 
Long-acting benzodiazepines:  




Short-acting benzodiazepines in high doses:  
N05BA06 lorazepam > 3 mg,  
N05BA04 oxazepam > 60 mg,  
N05BA12 alprazolam > 2 mg,  
N05CD07  temazepam > 15 mg,   
N05CD05 triazolam > 0.25 mg 
13.9 (276) 




N06AB03 fluoxetine daily 1.3 (26) 
N05BB01 hydroxyzine 7.1 (141) 
The table excludes PIDs available in Finland in 2003 but not used among our study 
population: barbiturates, belladonna alkaloids, clonidine, cyclandelate diphenhydramine, 
indomethacin, ketorolac, pethidine, methyltestosterone, short-acting nifedipine, and 
tripelennamine.  
The codes preceding the drug names refer to the ATC code.  
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5.6 Drug-drug interactions 
Altogether 4.8% of all residents were susceptible to a class D drug-drug 
interaction according to SFINX; two residents were susceptible to two class D 
interactions. Residents exposed to potential DDIs were more likely than others to be 
younger (mean age 81.8 years vs. 83.8 years, p=0.01), to have had a previous 
stroke (45.6% vs. 29.0%, p=0.002), to use psychotropics (89.6% vs. 79.2%, 
p=0.01), to be unable to move independently (40.6% vs. 29.8%, p=0.03), to 
consume a higher number of drugs (9.8 vs. 7.8, p < 0.001), and to be exposed to 
polypharmacy (58.3% vs. 42.0%, p=0.002). Of PID users and non-users, 6.6% and 
3.9%, respectively, were susceptible to class D interactions (p=0.006). Residents 
exposed to DDIs showed no significant differences in gender, level of education, 
widowhood, depression, diagnosis of dementia, or malnutrition from residents 
unexposed to DDIs (see Paper IV: Results). 
Of all carbamazepine users (n=67), 24% (n=16) were exposed to a potential class 
D DDI. Of codeine users (n=63), 21% (n=13) used a drug inhibiting the formation of 
morphine from prodrug codeine. Of potassium users (n=314), 11% (n=36) used a 
potassium-sparing diuretic, and were therefore at risk for hyperkalemia. Of warfarin 
users (n=157), 3% (n=5) used NSAID simultaneously, thereby increasing their risk 
for bleeding (see Paper IV: Results). 
5.7 Prescribing in public and private nursing homes 
Residents in private nursing homes were older, more often female, better 
nourished, and had a higher Charlson comorbidity index than did those residing in 
public nursing homes (Table 8). Despite these factors, residents in private nursing 
homes had a lower number of daily drugs than did residents in public nursing homes 
[7.58 (SD 3.4) vs. 8.28 (SD 3.7) p < 0.001] and were less often exposed to 
polypharmacy (36.6 vs. 44.6, p < 0.001). The prevalence of laxatives among 
residents in private nursing homes was lower than among those in public ones: 
52.7% vs. 58.3%, p=0.013, respectively. No differences existed in the use of 
psychotropic drugs (p=0.87) or potentially inappropriate drugs (p=0.91) or exposure 
to drug-drug interactions (p=0.28).  
In multivariate logistic regression analysis, in which those factors statistically 
significant in the univariate analysis served as covariates, residents in private nursing 




6.1 Study population and methods 
The study population for Studies I, II, and IV comprised 1987 aged long-term 
residents of nursing homes, or 82% of all nursing home residents in Helsinki in 2003; 
Study III (n=2114) included 87% of all residents. The exclusion criteria were short-
term residency, refusal to participate, and insufficient information on drug use. For 
Studies I, II, and IV, we excluded residents younger than 65 years. 
The mean age in Studies I, II, and IV was 84 years, and 83 years in Study III. Of 
all residents, 28% were malnourished and 60% were at risk for malnutrition. The 
mean Charlson comorbidity index was 2.12, and the mean number of drugs 
consumed daily was 7.9. Of all residents, 40% consumed more than nine drugs daily 
and were exposed to polypharmacy. 
The inclusion of all nursing homes in Helsinki and the high response rate provided 
a reliable picture of prescribing among nursing home residents. Collecting medical 
data directly from residents’ medical records rather than using computerized data 
records increased the accuracy and reliability of the results. However, errors can 
occur when completing the questionnaires and entering the data into electronic form. 
To minimize the coding of errors, a researcher afterwards compared each resident’s 
medication list in the questionnaire to the electronic version of the list. The data were 
collected without personal identification information and remained anonymous. 
Identifying residents in order to complete missing information or for future analyses 
was impossible. Consequently, the cross-sectional study design permits the analysis 
of associations, not of causalities or trends.  
Those residents whose medication records indicated a regular drug administration 
were classified as drug users. Others, including those residents using a drug on an as-
needed basis, were classified as non-users. This may have influenced our results; 
consequently, drug prevalence may actually be higher. This especially concerns drugs 
often used on an as-needed basis, such as laxatives, analgesics, or hypnotics. As a 
result, the association between laxative use and investigated factors may be stronger 
than reported here. However, the information on as-needed drugs is less reliable than 
on drugs administered regularly, so as-needed drugs were excluded from the 
analyses. 
Residents with dementia were identified by the diagnoses in their medical records 
and by the medications they were receiving. Although a large percentage (69.5%) of 
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residents had received an active diagnosis of dementia, some cases of dementia or 
other diseases may have gone undetected.  
6.2 Psychotropic medications 
In our study, four in five nursing home residents received psychotropic drugs. The 
prevalence was high compared to that of international studies, and is probably due to 
the frequent use of antipsychotics and antidepressants. The use of anxiolytics and 
hypnotics in our population, however, was moderate compared to that of other 
studies.  
Hypnotics and anxiolytics cause falls and fractures in the elderly (Leipzig et al. 
1999, Cumming 1998), and evidence of their impact on behavioral and psychotic 
symptoms of dementia are lacking (Sink et al. 2005). Consequently, less frequent use 
of these drugs seems appropriate. The doses of antipsychotics and anxiolytics in our 
population were considerably lower than those in the Defined Daily Doses (ATC DDD 
2009), which is appropriate since DDDs are determined for younger adults and, 
sometimes, for different indications. 
Male residents used conventional antipsychotics and anxiolytics other than 
benzodiazepines significantly more often than did female residents. The prevalence of 
SSRIs was higher among female residents. Previous nursing home studies have 
reported similar findings in the use of antipsychotics and antidepressants (van Dijk et 
al. 2000, Ruths et al. 2001, Sorensen et al. 2001). Perhaps the more frequent use of 
antipsychotics in males is due to aggressive symptoms, and perhaps depression 
among female residents is better recognized in institutional settings. The mean age of 
male residents was lower in our study, and some researchers have suggested that the 
lower age of male residents explains the higher prevalence of antipsychotics (Ruths et 
al. 2001). 
The high use of psychotropics in our nursing homes may reflect the overall 
prescribing culture of psychotropic drugs in Finland. Previous studies have noted the 
association of facility characteristics with the use of antipsychotics (Hughes et al. 
2000), suggesting that the high prevalence of antipsychotics may be related to the 
low staffing rate in Finnish nursing homes. The mean actual staffing level in nursing 
homes in Finland has been 0.43 nurses per client on weekdays and 0.35 on weekends 
(Noro et al. 2005). The National Framework for High-Quality Care and Services for 
older people suggests a minimum staffing level of 0.5 to 0.6 nurses per client, and a 
good staffing level is 0.8 nurses per client (Ministry of Social Affairs and Health 2008). 
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The use of psychotropic drugs also depends on resident characteristics such as 
dementia, psychiatric diagnoses, and behavioral symptoms. The prevalence of 
dementia in our nursing homes (70%) is notably higher than that reported in 
Denmark (Sorensen et al. 2001) and the US (50%) (Pedone et al. 2004). The 
frequent use of psychotropics among patients with dementia is partly due to the need 
to control behavioral and psychotic symptoms of dementia, which present the highest 
risk for institutionalization (Phillips & Diwan 2003). The characteristics, diagnoses, 
and symptoms of nursing home residents vary widely between countries and 
complicate international comparisons.  
A previous Helsinki study on psychotropic drugs among nursing home residents 
with dementia (Pitkala et al. 2004) allows for some conservative comparisons, 
however. In 1999-2000, the prevalence of psychotropic medication among residents 
with dementia was 87% compared to 80% in 2003. The prevalence of conventional 
antipsychotics was more than twice as high in 1999-2000 as in 2003 (41% vs. 18%), 
whereas atypical antipsychotics were used by 13% of residents with dementia 
diagnosis in 1999-2000 and by 28% in 2003. The prevalences of antidepressants, 
anxiolytics, and hypnotics among residents with a diagnosis of dementia were 47%, 
38%, and 49% in 1999-2000, and 41%, 25%, and 23% in 2003. The Minimum Data 
Set of Finnish nursing homes suggests that the use of antipsychotics, anxiolytics, and 
hypnotics is indeed decreasing (Noro et al. 2005).  
The diminishing use of psychotropic drugs and the transition from conventional 
antipsychotics to atypical antipsychotics represent favorable developments. A growing 
body of evidence suggests that some non-pharmacological therapies may positively 
affect the treatment of behavioral and psychotic symptoms of dementia and may 
occasionally serve as an alternative to pharmacological therapy (Thorgrimsen et al. 
2003, Burns et al. 2002, Spector et al. 2000). However, many institutionalized 
patients require pharmacological symptom control (Forbes 1998). 
Of those residents with a diagnosis of dementia, 3% received AChE in 1999-2000 
(Pitkala et al. 2004), and 10% in 2003. The use of AChE still seems to be less 
frequent than in US nursing homes, however. In a study taking advantage of the 
Minimum Data Set (N=174 659), 30% of newly admitted residents with mild to 
moderate dementia received donepezil (Pedone et al. 2004). AChEs favorably affect 
behavioral and psychotic symptoms of dementia (Rosler 2002, McKeith et al. 2000, 
Tariot et al. 2000), and have been recommended as the primary medication for this 
indication (Sink et al. 2005). The main indication of AChEs in Finland has previously 
been related to the care of patients with dementia in order to postpone their 
institutionalization. This indication, and its high cost, has discouraged the use of 
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AChEs in nursing homes. Accumulating evidence indicates that AChEs benefit patients 
with dementia, even at severe stages of the disease, as well as those already 
institutionalized (Tariot 2003). 
Those residents with no diagnosis of dementia received even more psychotropic 
drugs than did those with a diagnosis of dementia (85% vs. 78%); such residents 
received antidepressants, long-acting benzodiazepines, and hypnotics significantly 
more often. Some studies have suggested that depression in residents with a 
diagnosis of dementia is poorly recognized and undertreated (Elmstahl et al. 1998). 
Those residents with no diagnosis of dementia include psychiatric patients and, 
probably, undiagnosed dementia patients. However, the overall high use of 
psychotropics suggests a need to review the indications themselves. 
6.3 Laxatives 
More than half of nursing home residents used at least one laxative regularly. 
Osmotic laxatives were the most common. Stimulant laxatives were prescribed for 
14% of residents, and more than one in ten residents used at least two regularly 
administered laxatives simultaneously.  
In multivariate logistic regression analysis, advanced age, inability to move 
independently, a high number of drugs, malnutrition, chewing problems, and 
Parkinson’s disease were associated with laxative use.  Eating snacks between meals 
was associated with lower risk for laxative use. Of the potentially constipation-
inducing drugs, several medications were significantly associated with regular laxative 
use.   
The prevalence of laxative use in nursing homes in Helsinki is very similar to that 
of previous international studies (van Dijk et al. 1998, Harari et al. 1995, Monane et 
al. 1993, Brocklehurst et al. 1999). In the US, 54% of nursing home residents used 
laxatives, and 26% of all residents received bulk laxatives, 18% osmotic laxatives, 
and 16% stimulant laxatives (Phillips et al. 2001). In Britain, 60% of residents 
received laxatives more than once weekly. Of all residents, 34% used lactulose, and 
22% senna (Brocklehurst et al. 1999).    
As in some previous studies (van Dijk et al. 1998, Harari et al. 1995, Monane et 
al. 1993), laxatives served as a proxy drug for constipation, even though the MNA 
questionnaire included a question inquiring whether the resident experiences 
constipation. In a population with a high prevalence of laxatives, studying 
constipation is challenging; as a result, we focused on its consequence: the use of 
laxatives. Laxatives are seldom used for any other indication than constipation. 
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However, we do not know whether all laxative users in our study population meet the 
diagnostic criteria for constipation, and if all residents with constipation receive 
laxatives.  
Eating snacks between meals was associated with lower risk for chronic laxative 
use in multivariate logistic regression analysis. In Finland, a typical snack includes rye 
bread with a topping, or a dairy product such as yoghurt.  Dark rye bread is rich in 
fiber, and dairy products contain lactose, which acts as an osmotic laxative. Snacks 
can also influence laxative use by increasing bulk in the gastrointestinal tract.  
In a Norwegian nursing home study, the use of laxatives was associated with the 
concurrent use of opioids, anti-parkinsonian drugs, and the total number of drugs 
used, but not with the use of drugs with anticholinergic properties (Nygaard et al. 
2003). The constipation-inducing characteristics of opioids, antacids, diuretics, 
tricyclic antidepressants, histamine-2 blockers, and anticholinergic drugs used for 
urine incontinence are well known.  However, the association between laxative use 
and non-selective NSAIDs and calcium channel blockers other than verapamil and 
nifedipine proved interesting. Yet, the constipation-inducing characteristics of NSAIDs, 
which inhibit the normal production of prostaglandins, appear in the literature 
(Romero et al. 1996).   
The high prevalence of constipation in nursing home residents is, of course, only 
partly due to ADRs. In a Dutch nursing home study in which laxative use served as a 
proxy for constipation and each resident underwent a prescription sequence analysis, 
only those drugs that, according to their product summaries and the literature, exhibit 
a moderate to strong constipating effect correlated with laxative use (van Dijk et al. 
1998). Residents with depression, diabetes mellitus, or relatively good mobility 
showed a higher risk for drug-induced constipation. Calcium and ferrous salts, and 
verapamil correlated with constipation (van Dijk et al. 1998).  The association 
between a certain drug and a laxative may stem from the disease for which the drug 
is prescribed, a symptom of this disease (e.g. immobility), or the constipation-
inducing characteristic of the drug. 
Essential keystones in treating constipation are a sufficient supply of fluids and 
fiber, exercise, or physical activity, fiber-containing snacks, and, if needed, laxatives. 
Using one drug to treat the adverse drug reaction of another is undesirable (Harari et 
al. 1995). Nursing home residents use many drugs and therefore require frequent 
evaluation of their mediations. 
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6.4 Vitamin D and calcium supplements 
Regardless of the recommendation of vitamin D supplementation to all 
institutionalized older people, less than one third of nursing home residents received 
vitamin D, and even fewer received calcium. Only one in five residents received both 
vitamin D and calcium. Eating snacks between meals, being well nourished, and 
regular weight monitoring were associated with the use of vitamin D supplements.  
Because Finland is located at high northern latitudes, the population’s exposure to 
sunshine is limited during most of the year. In addition, older people residing in 
institutions spend most of their time indoors regardless of the season. In addition, the 
cutaneous intake of cholecalciferol decreases with age (Heaney 2004).  
Our study indicates that recommendations for vitamin D supplementation are 
poorly implemented in practice. Reasons for not complying with recommendations 
may be numerous. Nursing homes may be attempting to avoid polypharmacy or to 
reduce medication costs, residents may be experiencing difficulties taking the 
supplements, or the recommendations are simply being ignored.  
An increasing body of evidence shows that vitamin D supplementation plays a role 
in preventing falls and fractures, and the supplementation dose should be at least 800 
IU (20µg) daily (Bischoff-Ferrari et al. 2005, Bischoff-Ferrari et al. 2004a, Bischoff-
Ferrari & Dawson-Hughes 2007, Venning 2005, Broe et al. 2007). The 
recommendation of vitamin D supplementation for institutionalized elderly has 
recently been updated to 800 IU (20μg) (Suominen et al. 2010). Whether the new 
recommendation will raise the prevalence of vitamin D supplementation among 
nursing home residents remains to be seen. At present, vitamin D supplements are 
over-the-counter drugs. The availability of a prescription preparation of vitamin D 
could affect prescribing patterns.   
6.5 Potentially inappropriate drugs 
One third of nursing home residents in Helsinki received PIDs according to the 
Beers 2003 criteria. Of particular concern was the proportion of residents receiving 
more than one PID simultaneously (6%). PID users were more likely to have 
polypharmacy, psychotropic drugs, and no diagnosis of dementia than were those not 
receiving PIDs. 
The most prevalent PID was temazepam in greater doses than recommended. 
Temazepam is a benzodiazepine with a half-life of 5 h to 20 h (Pharmaca Fennica 
2010). In Finland, temazepam generally serves as a hypnotic administered in the 
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evening. Nitrofurantoin, which in Finland is used for the short-term treatment of acute 
urinary tract infections, is considered inappropriate for older adults because of its 
potential for renal impairment (Fick et al. 2003), nitrofurantoin-induced pulmonary 
toxicity (Witten 1989), or ineffectiveness in renal impairment (Kunin 2004). The 
frequent use of hydroxyzine, an antihistamine with strong anti-cholinergic properties, 
is inappropriate indeed. 
The Beers criteria classify bisacodyl, cascara sacrada, and castor oil as stimulant 
laxatives inappropriate for use in older adults, except when co-administered with 
opiates. Of these, only bisacodyl was used in Finland in 2003, and less than one 
percent of residents was exposed to stimulant laxatives without receiving opiates 
simultaneously. If, however, we include in the analysis other stimulant laxatives 
available in Finland in 2003, then 12% of residents were receiving stimulant laxatives. 
This demonstrates a focal problem in compiling explicit criteria: applying the criteria 
in another country may be difficult. 
Several previous studies have reported PID use according to the Beers criteria 
among nursing home residents. Although these studies show a wide range of 
prevalence in PID use, direct comparison is difficult because the criteria are often 
modified for local conditions. 
In an earlier Finnish study, the prevalence of PIDs among institutionalized older 
people in 1999-2000 was strikingly similar to that in the present study (36.2% vs. 
34.4%) (Raivio et al. 2006). Interestingly, after a two-year follow-up, the study group 
found no difference in the number of acute hospital days, hospital admissions, or 
mortality curves between PID users and non-users. The results concerning the 
adverse drug events of PIDs, according to the Beers criteria, have indeed been 
contradictory (Spinewine et al. 2007, Wagner et al. 2007, Lau et al. 2005). 
Our study used explicit criteria to assess PID prescribing, and the study design 
allows no use of clinical judgement to evaluate the appropriateness of prescribing for 
an individual patient. In addition, using explicit criteria in a cross-sectional study 
enabled us to determine the prevalence of potentially inappropriate drugs, but not the 
actual outcome of potentially inappropriate prescribing. Sometimes, prescribing a 
potentially inappropriate drug is actually appropriate. Best current practice for 
prescribing for geriatric patients relies on the regular evaluation of the safety and 
efficacy of each medication and medication combination (Hilmer et al. 2007b). Even 
though polypharmacy carries several disadvantages, reducing the number of drugs is 
difficult (Pitkala et al. 2001).  
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6.6 Drug-drug interactions 
Less than 5% of the nursing home residents in Helsinki were susceptible to 
potential clinically significant drug-drug interactions. Residents exposed to DDIs were 
more likely to use PIDs and to be exposed to polypharmacy.  
More than half of the DDIs in our study population presented a risk for losing the 
treatment effect. However, some of the DDIs may lead to a dramatically adverse 
outcome. The simultaneous use of warfarin and NSAIDs (five residents) is of 
particular concern indeed. Seven residents were exposed to a DDI that could 
potentially cause a cardio-depressive effect, and 36 residents were exposed to a DDI 
that could lead to hyperkalemia. The latter is perhaps not so problematic in a nursing 
home setting, since the residents can be followed up for their pulse, 
electrocardiograms, and serum potassium. However, the majority of the remaining 
DDIs in our population could lead to a loss of treatment effect, which may lower the 
resident’s quality of life. 
A large Swedish study investigating potential DDIs from the prescriptions of over 
8000 home-dwelling individuals, found that age and polypharmacy correlated 
positively with DDIs (Astrand et al. 2006). Of all the potential DDIs detected, clinically 
significant class D interactions constituted 8%. The study utilized the Swedish 
classification system of DDIs (www.fass.se), which preceded the SFINX database and 
is embedded in it.  
A study performed in six European countries and using the same Swedish 
classification system reported a prevalence of class D DDIs among elderly outpatients 
ranging from 4% to 12%. The most common DDIs in this study were ipratropium 
bromide and β2-agonists, potassium and potassium-sparing agents, and 
antithrombotic agents combined with NSAIDs or acetylsalicylic acid (Bjorkman et al. 
2002). 
Some authors have suggested that to avoid drug interactions and compliance 
problems, drug regimes for older people should remain as simple as possible and the 
goal should be one or two treatments daily (Turnheim 2004). The primary question in 
prescribing for the elderly should not be which drug to choose or how to administer it, 
but whether the drug is actually necessary (Turnheim 2004). Simpler drug regimens 
may be achieved by prescribing drugs that can be taken once daily and or by 
choosing a combination pill when adding a second drug (Lee 1998). 
Fortunately, a potential interaction does not necessarily lead to an actual adverse 
outcome. Assessment of actual interactions is based on clinical judgement (Mallet et 
al. 2007) or, in some cases, laboratory tests. Tools for screening potential interactions 
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are important for the prevention of actual ones. Computerized interaction programs 
such as SFINX may help the professional to identify patients susceptible to 
interactions, but do not substitute for clinical knowledge (Saarelma et al. 2006). 
SFINX points out the pharmacokinetic interaction of two drugs, but does not warn of 
parallel or contrary drug effects (Saarelma et al. 2006). 
6.7 Public and private nursing homes 
Of all residents, 46% were residing in public, and 54% in private nursing homes.  
Residents in private nursing homes were older, more often female, and had higher 
MNA scores and Charlson comorbidity indices than did residents in public nursing 
homes. Several morbidities predispose people to polypharmacy, yet residents in 
private nursing homes were less often exposed to polypharmacy than were residents 
in public nursing homes. Avoiding polypharmacy is indeed appropriate. However, 
these data do not enable one to evaluate the appropriateness of prescribing on the 
level of the individual resident, so potential underuse or overuse often remains 
undetected. In addition, we do not know whether these institutions follow identical 
practices in maintaining their medication records. 
The new Act on Public Procurement took effect in 2007 (www.finlex.fi). This act 
defines the standards for the procurement of goods and services in public 
administration, including nursing home services publicly funded as a part of the 
Finnish social security and health care system. The data for this study were collected 
in 2003, and the new act may have affected the quality of services purchased from 
the private sector since the data collection. 
6.8 Perspectives on prescribing in nursing homes 
This cross-sectional study describes the use of psychotropic drugs, laxatives, 
vitamin D and calcium supplements, and potentially inappropriate drugs as well as 
exposure to clinically significant drug-drug interactions in nursing homes. Although 
the study design does not allow for assessment of the appropriateness of prescribing 
at the level of the individual resident, using explicit criteria and assessing drug 
prevalence, along with factors associated with drug use, nevertheless provide us with 
a comprehensive picture of drug therapy among nursing home residents.  
A more detailed picture of prescribing, including overprescribing and 
underprescribing at the level of the individual resident level, could be achieved with 
implicit criteria and the geriatric assessment of residents’ diagnoses and prescriptions. 
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However, such a methodology is time-consuming and laborious, and would thus be 
feasible only for a smaller sample representative of all nursing home residents.  
In Helsinki, the use of psychotropic drugs is much more common than figures for 
international nursing indicate. This disparity is partly due to patient characteristics, 
but nevertheless raises concerns over the appropriateness of indications for 
psychotropic drug use. In many cases, psychotropic drugs are necessary and form an 
integral part of appropriate treatment. However, we should pay close attention to the 
indications for psychotropic drug use every time they are prescribed or when 
assessing a resident’s existing medication record.  
Residents eating snacks between meals used laxatives less often than did 
residents who ate no such snacks. Good nutritional care can indeed impact one’s need 
for drugs. Vitamin D and calcium supplementation are easy and simple means to 
ensure an adequate supply of necessary micronutrients. Adhering to the national 
guidelines of vitamin D supplementation for institutionalized older people should be 
self-evident.  
Due to the anonymous data of nursing home residents in the present study, a real 
follow-up study would be inappropriate. Changes in prescribing practices could be 
investigated, however, even though the medication records of individual residents 
cannot be linked. For example, changes in the prevalence of AChEs and other 
psychotropics among residents with a diagnosis of dementia would be an especially 
interesting topic for future study. 
Criteria for appropriate or good-quality drug use are useful aids for clinical 
decision-making. They should, however, be considered suggestions, not rules, for 
proper prescribing. Rather than focusing on diseases or blindly following guidelines, 
the prescriber should concentrate on the unique medication needs of each individual 
patient and aim for optimal drug therapy which meets the individual patient’s needs. 
Especially when treating older patients, the indication, choice, dosage and duration of 





The prevalence of psychotropic drugs among nursing home residents is very high. 
In addition, many nursing home residents are exposed to polypharmacy. Regardless 
of the national recommendations for vitamin D supplementation, the prevalence of 
vitamin D and calcium supplementation is alarmingly low. Three of the most 
frequently prescribed potentially inappropriate drugs for older adults, according to the 
Beers criteria, comprise more than three quarters of all potentially inappropriate 
drugs. Potentially clinically significant drug-drug interactions seem not to be a focal 
problem in nursing homes, and the prevalence of laxatives seems to be in line with 
that in international studies. The quality of drug therapy may be higher in private 
nursing homes than in public nursing homes. 
Paying close attention to proper indications of psychotropic drugs would likely 
improve the quality of psychotropic prescribing in nursing homes. So would replacing 
potentially inappropriate drugs with more appropriate ones. Moreover, adhering to the 
guidelines of vitamin D supplementation for elderly institutionalized people in all 
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ASUKKAAN RAVITSEMUSTILAN ARVIOINTI (MNA) 20.1.2003 
 
Anna tutkimallesi asukkaalle numero, __________, laita annetulle listalle muistiin asukkaan 
numero, 
nimi ja sotu. Säilytä lista osastolla. 
Vanhainkoti: _______________________________, no: ________ 
Osasto: _____________________, no: __________ 
Vanhainkoti on: kaupungin oma _____, ostopalvelu _____ 
Päivämäärä: _________________ 
Pituus ___________ cm 
Paino nyt ____________ kg, paino syksyllä 2002 __________ kg 
Kantapää-polvi _________ cm 
Kuinka kauan asukas on ollut kyseisessä vanhainkodissa? ____vuotta ____ kuukautta 
 
Seuraavissa kysymyksissä ympyröi yksi vastausvaihtoehdoista ja kirjaa ympyröimäsi numero 




1. Onko ravinnonsaanti vähentynyt viimeisen kolmen kuukauden aikana ruokahaluttomuuden, 
ruoansulatusongelmien, puremis- tai nielemisvaikeuksien takia? 
0 = Kyllä, ravinnonsaanti on vähentynyt huomattavasti 
1 = Kyllä, ravinnonsaanti on vähentynyt hieman 
2 = Ei muutoksia 
 
2. Painonpudotus kolmen viime kuukauden aikana? 
0 = Painonpudotus yli 3 kg 
1 = Ei tiedä 
2 = Painonpudotus 1-3 kg 
3 = Ei painonpudotusta 
 
3. Liikkuminen? 
0 = Vuode- tai pyörätuolipotilas 
1 = Pääsee ylös sängystä, mutta ei käy ulkona 
2 = Liikkuu ulkona 
 
4. Onko viimeisen kolmen kuukauden aikana ollut psyykkistä stressiä tai akuutti sairaus? 
0 = Kyllä 
2= Ei 
 
5. Neuropsykologiset ongelmat? 
0 = Dementia, depressio tai neuropsykologinen ongelma 
1 = Lievä dementia, depressio tai neuropsykologinen ongelma 
2 = Ei ongelmia 
 
6. Painoindeksi eli BMI (=paino / (pituus)2 kg/m2) 
0 = BMI on alle 19 
1 = BMI on 19 tai yli, mutta alle 21 
2 = BMI on 21 tai yli, mutta alle 23 




Pisteet yhteensä (1. sivu) 
ARVIOINTI 
 
7. Asuuko haastateltava kotona? 
0 = Ei 
1 = Kyllä 
 
8. Onko päivittäisessä käytössä enemmän kuin 3 reseptilääkettä? 
0 = Kyllä 
1 = Ei 
 
9. Painehaavaumia tai muita haavoja iholla? 
0 = Kyllä 
1 = Ei 
 
10. Päivittäiset lämpimät ateriat (sisältää puurot ja vellit)? 
0 = 1 ateria 
1 = 2 ateriaa 
2 = 3 ateriaa 
 
11. Sisältääkö ruokavalio vähintään 
Ei     Kyllä 
Yhden annoksen maitovalmisteita 
(maito, juusto, piimä, viili) __ __ 
Kaksi annosta tai enemmän kananmunia 
viikossa (myös ruuissa, esim. laatikot) __ __ 
Lihaa, kalaa tai linnun lihaa joka päivä __ __ 
 
0 = Jos 0 tai 1 kyllä –vastausta 
0.5= Jos 2 kyllä -vastausta 
1 = Jos 3 kyllä –vastausta 
 
12. Kuuluuko päivittäiseen ruokavalioon kaksi tai useampia annoksia hedelmiä tai kasviksia? 
0 = Ei 
1 = Kyllä 
 
13. Päivittäinen nesteen juonti? 
0 = Alle 3 lasillista 
0.5 = 3-5 lasillista 
1 = Enemmän kuin 5 lasillista 
 
14. Ruokailu 
0 = Tarvitsee paljon apua tai on syötettävä 
1 = Syö itse, mutta tarvitsee hieman apua 
2 = Syö itse ongelmitta 
 
15. Oma näkemys ravitsemustilasta 
0 = Vaikea virhe- tai aliravitsemus 
1 = Ei tiedä tai lievä virhe- tai aliravitsemus 






16. Oma näkemys terveydentilasta verrattuna muihin samanikäisiin 
0 = Ei yhtä hyvä 
0.5 = Ei tiedä 
1 = Yhtä hyvä 
2 = Parempi 
 
17. Olkavarren keskikohdan ympärysmitta (OVY cm) 
0 = OVY on alle 21 cm 
0.5 = OVY on 21-22 cm 
1.0 = OVY on yli 22 cm 
 
18. Pohkeen ympärysmitta (PYM cm) 
0 = PYM on alle 31 cm 
1 = PYM on 31 cm tai enemmän 
 
Pisteet yhteensä (2+3. sivu) 






































Kysymyksien vastausvaihtoehdoista ympyröidään sopivin numero (vain yksi). 
 
19. Ikä: _______ vuotta 
 
20. Sukupuoli? 
1 = Nainen 
2 = Mies 
 
21. Siviilisääty? 
1 = Naimaton 
2 = Leski 
3 = Eronnut 
4 = Avio- tai avoliitossa 
 
22. Koulutus? 
1 = Kansakoulu tai vähemmän 
2 = Ammattikoulu 
3 = Keskikoulu 
4 = Lukio 
5 = Opistoasteen ammattikoulutus 
6 = Korkeakoulu 
 
23. Minkälaisessa työssä asukas on toiminut pääsääntöisesti elämänsä aikana? 
1 = Maanviljelys, karjanhoito, metsätyö, emännän työt 
2 = Tehdas-, kaivos-, rakennus-, tai muu vastaava työ 
3 = Toimistotyö, henkinen työ, palvelutyö 
4 = Muu, mikä? ______________________________ 
 
24. Mikäli yksikössä on käytössä RAI, mitkä ovat asukkaan viimeisimmän RAI – mittauksen 
tulokset? 
1 = CPS __________ 
2 = BMI ___________ 
3 = ADL __________ 
4 = Kipuskaala __________ 
5 = Masennusskaala __________ 
 
25. Onko asukkaalla joku erityisruokavalio? Ei            Kyllä 
1 = Laktoositon 1 2 
2 = Keliakia 1 2 
3 = Diabetes (insuliini) 1 2 
4 = Diabetes (ei insuliini) 1 2 
5 = Sappi 1 2 
6 = Kihti 1 2 
7 = Kasvis 1 2 
8 = Muu, mikä __________ 1 2 
 
26. Minkä verran asukas syö pääaterioiden suositellusta annoskoosta keskimäärin? 
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1 = Vähemmän kuin puolet 
2 = Puolet 
3 = Lähes kaiken 
4 = Kaiken 
27. Millainen on asukkaan ruoan rakenne? 
1 = Nestemäinen 
2 = Sosemainen 
3 = Pehmeä 
4 = Kiinteä 
 
28. Syökö asukas välipaloja? 
1 = Ei 
2 = Kyllä 
 
29. Käytetäänkö asukkaalla täydennysravintovalmisteita (esim. Nutrison, Semper, Fortimel, 
Ensini, Additene jne.)? 
1 = Ei 
2 = Kyllä 
 
30. Saako asukas kalkkivalmistetta 
1 = Ei 
2 = Kyllä 
 
31. Saako asukas D-vitamiinivalmistetta 
1 = Ei 
2 = Kyllä 
 
32. Kuinka usein asukkaan paino mitataan keskimäärin? 
1 = Ei koskaan 
2 = Kerran vuodessa tai harvemmin 
3 = Kahdesti - kuudesti vuodessa 
4 = Yli kuusi kertaa vuodessa 
 
33. Kirjataanko asukkaan vatsantoiminta? 
1 = Ei 
2 = Kyllä 
 
34. Onko asukkaalla seuraavia ruokailuun ja suuhun sekä ruoansulatuselimistöön liittyviä 
ongelmia?   Ei     Kyllä 
1 = Puremisongelmia 1 2 
2 = Kuiva suu 1 2 
3 = Kipua suussa 1 2 
4 = Nielemisongelmia 1 2 
5 = Ummetusta 1 2 
6 = Ripulia 1 2 
7 = Oksentelua 1 2 
8 = Ruoalla sotkemista/ruoan pois työntämistä tai 1 2 
sylkemistä/malttamattomuutta syödessä 
9= Muita ongelmia, mitä ______________________ 1 2 
 
35. Mikä on asukkaan hampaiston tila syödessä? 
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1 = Hampaaton, ei proteesia 
2 = Kokoproteesi sekä ylä- että alaleuassa 
3 = Hampaaton, mutta joko ylä- tai alaleuan kokoproteesi ja/tai muita osaproteeseja 
4 = Omia hampaita ja yksi tai useampia proteeseja 
5 = Vain omia hampaita 
36. Onko asukkaalla seuraavia sairauksia tai onko asukas sairastanut aikaisemmin? 
Ei     Kyllä 
1 = Sokeritauti 1 2 
2 = Sepelvaltimotauti 1 2 
3 = Sydänveritulppa eli sydäninfarkti 1 2 
4 = Aivohalvaus tai aivoverenkiertohäiriöitä 1 2 
5 = Dementia 1 2 
6 = Parkinsonin tauti 1 2 
7 = Maha- tai pohjukaissuolen haavauma 1 2 
8 = Muu krooninen suolistosairaus 1 2 
Jos on, mikä _________________ 
9 = Lonkkamurtuma 1 2 
10. = Syöpä 1 2 
Jos on, mikä _________________ 
Jos on, milloin todettu __________ 
11. = Jokin muu pitkäaikainen sairaus 1 2 
Jos on, mikä _________________ 
 
37. Asukkaan säännöllisesti käyttämät, lääkärin määräämät lääkkeet ja vitamiinit. (Kirjoita 
alla 
olevaan tilaan valmisteiden nimet tai kopioi lääkelista ilman asukkaan nimeä ja 
henkilötunnusta ja niittaa se tämän lomakkeen perään.) 
 
1 = ______________________________________ 
2 = ______________________________________ 
3 = ______________________________________ 
4 = ______________________________________ 
5 = ______________________________________ 
6 = ______________________________________ 
7 = ______________________________________ 
8 = ______________________________________ 
9 = ______________________________________ 
10. = _____________________________________ 
11.= _____________________________________ 
12. = _____________________________________ 
13. = _____________________________________ 
14. = _____________________________________ 
15. = _____________________________________ 
16. = _____________________________________ 
17. = _____________________________________ 
18. = _____________________________________ 
19. = _____________________________________ 
20. = Listaa kaikki muut lääkkeet:_______________ 
 
Lomakkeet palautetaan yhdessä osastonhoitajan täyttämän lomakkeen kanssa __________ 
mennessä Vanhusten laitos- ja asumispalveluihin. 
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Original publications 
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